ESK981  2017 -065  
Karmanos Cancer Institute   
Esanik Therapeutics Inc.  1 of 67 Version date: 7/2/2019  An Open -Label, Parallel, Phase II Study of Single -Agent Oral ESK981 in 
Men with Metastatic Castrat ion-Resistant Prostate Cancer ( mCRPC)  
Prostate Cancer Clinical Trials Consortium, LLC (PCCTC)  
PCCTC #:  c16-178 
IND  #: 136687  
Karmanos Cancer Institute/Esanik Therapeutics  
 
Principal Investigator  [INVESTIGATOR_820612] I. Heath, MD FACP  
Karmanos Cancer Institute  
4100 John R  
Detroit, MI [ZIP_CODE]  
Phone: 313 -576 -8717  
Fax: 313 -576 -8767  
Email : [EMAIL_13698]  
 Lance K. Heilbrun, PhD  
Karmanos Cancer Institute  
[ADDRESS_1137303] Canfield  
Detroit, MI [ZIP_CODE]  
Phone: 313 -576 -8652  
Fax: 313 -576 -8656  
Email : Heilbru [EMAIL_15596]  
Co-investigator s 
 
Ulka Vaishampayan , MD  
Karmanos Cancer Institute  
4100 John R  
Detroit, MI [ZIP_CODE]  
Phone: 313 -576 -8718  
Fax: 313 -576 -8767  
Email: [EMAIL_3400]  
 
Joseph Fontana, MD , PhD  
Karmanos Cancer Institute  
4100 John R  
Detroit, MI [ZIP_CODE]  
Phone: 313 -576 -8022  
Fax: 313 -576 -8767  
Email: [EMAIL_15597]  
 Laboratory  
 
University of Michigan:  
Pathology/MCTP  
c/o Erica Rabban  
[ADDRESS_1137304]., 5309 CCC  
Ann Arbor, MI [ZIP_CODE] -5940  
Email: [EMAIL_15598]  
Phone: 1 -734 -763 -2826  
 
 
 
  
Protocol Date : September 25, 2017  
Amendment 1: January 4, 201 8 
Amendment 2: February 26, 201 8 
Amendment 3: April 24, 201 8 
Amendment 4: July 27, 2018  
Amendment 5: November 27, 2018  
ESK981  2017 -065  
Karmanos Cancer Institute   
Esanik Therapeutics Inc.  2 of 67 Version date: 7/2/2019  Amendment 6: January 12, 2019  
Amendment 7: July 2, [ADDRESS_1137305] or Ethics Committee. By  [CONTACT_11217], you agree that the information contained 
herein will not be disclosed to others without written authorization from the lead site/sponsor, 
except to the extent necessary to initiat e the study or conduct study -related activities.  
ESK981  2017 -065  
Karmanos Cancer Institute   
Esanik Therapeutics Inc.  3 of 67 Version date: 7/2/[ADDRESS_1137306] read the protocol specified below. In my formal capacity as Investigator, my duties include 
ensuring the safety of the study subjects enrolled under my supervision and providing  Esanik 
Therapeutics  with complete and timely information, as outlined in the protocol.  It is understood 
that all information pertaining to the study will be held strictly confidential and that this 
confidentiality requirement applies to all study staff at  this site. Furthermore, on behalf of the study 
staff and myself, I agree to maintain the procedures required to carry out the study in accordance 
with accepted good clinical practice ( GCP ) principles and to abide by [CONTACT_38114].  
 
 
 
 
 
Principal Investigator [INVESTIGATOR_7496]:  _______________________________________________________  
Principal Investigator [INVESTIGATOR_43146]:  _______________________________________________________  
Date:      _______________________________________________________  
 
  
ESK981  2017 -065  
Karmanos Cancer Institute   
Esanik  Therapeutics Inc.                                                   Page 4 of 67                                            Version date: 7/2/201 9
   
 TABLE OF CONTENTS  
1. INTRODUCTION  ................................ ................................ ................................ ................................ ................................ ..... 6 
 1.1 Disease Background ................................ ................................ ................................ ................................ ................................ ........ 6 
 1.2 Treatment Background  ................................ ................................ ................................ ................................ ................................ . 7 
 1.3 Rationale ……………………………………………… ……… ……………………………… ……………….. ……………… ..……….......15 
 1.4 Rationale for Correlative Studies…………………………………………………………………… ………………... ….…… ……16 
2. OBJECTIVES  ................................ ................................ ................................ ................................ ................................ ..........  17 
 2.1 Primary Objective  ................................ ................................ ................................ ................................ ................................ ..........  17 
 2.2 Secondary Objectives  ................................ ................................ ................................ ................................ ................................ ... 17 
 2.3 Correlative/Exploratory/Tertiary Objectives  ................................ ................................ ................................ ...................  [ADDRESS_1137307] REGISTRATION  ................................ ................................ .............................  20 
 4.1 Registration Procedure  ................................ ................................ ................................ ................................ ...............................  20 
 4.2 Survival Followup  ................................ ................................ ................................ ................................ ................................ ..........  21 
5.  TREATMENT/INTERVENTI ON PLAN………………… ………………………….. …………………………………… .………… .20 
 5.1 Removing Subjects from the Protocol…………………………………………………… ………………… …………..……… ...21 
 5.2 Definition of Compliance with Self-Adjusted Oral Agent ESK981………………………… ………………… ……..…22 
6. THERAPEUTIC AGENT  ................................ ................................ ................................ ................................ .....................  22 
 6.1 Description  of Treatments  ................................ ................................ ................................ ................................ .........................  22 
 6.2 ESK981 D rug Supply and Return .……… ………………… .………………… .……..…………………………… ..……..…........…22  
 6.3  Drug Accountability ………………………………………………………………………………… ...…………………… ……….……23 
ATTACHMENTS  ................................ ................................ ................................ ................................ ................................ ..... 24 
   Attachment 1:  ................................ ................................ ................................ ................................ ................................ ..............  25 
   Attachment 2:  ................................ ................................ ................................ ................................ ................................ ..............  26 
   Pharmacokinetics  ................................ ................................ ................................ ................................ ................................ ...... 27 
 6.4 Dosage Selected, Preparation, and Schedule of Administration  ................................ ................................ ...............  31 
 6.5 Dose Modifications  ................................ ................................ ................................ ................................ ................................ ........ 32 
 6.6 Management of Expected Toxicities  ................................ ................................ ................................ ................................ ...... 32 
 6.7 Concomitant Medications and Supportive Care  ................................ ................................ ................................ ...............  34 
7. SAFETY EVALUATION  ................................ ................................ ................................ ................................ ......................  35 
 7.1 Definitions  ................................ ................................ ................................ ................................ ................................ .........................  35 
 7.2 Recording and Grading of Adverse Events  ................................ ................................ ................................ .........................  37 
 7.3 Adverse Events Reporting  ................................ ................................ ................................ ................................ .........................  38 
 7.4   Serious Adverse Event Reporting  ................................ ................................ ................................ ................................ ...........  40 
 7.5   Procedure in case of Pregnancy  ................................ ................................ ................................ ................................ ..............  41 
8. CRITERIA FOR OUTCOME  ASSESSMENT/THERAPEUT IC RESPONSE ................................ ..............................  42 
 8.1 Outcome Assessment  ................................ ................................ ................................ ................................ ................................ ... 42 
 8.2 Therapeutic Response  ................................ ................................ ................................ ................................ ................................ . 43 
 8.3 Response Criteria  ................................ ................................ ................................ ................................ ................................ ...........  45 
 8.4 Confirmatory Measures/Duration of Response  ................................ ................................ ................................ ...............  [ADDRESS_1137308]  ................................ ................................ ................................ ................................ ..... 54 
11. STATISTICAL CONSIDER ATIONS  ................................ ................................ ................................ ...............................  54 
 11.1 Objectives  ................................ ................................ ................................ ................................ ................................ ......................  54 
 11.2 Endpoints  ................................ ................................ ................................ ................................ ................................ ......................  55 
11.3 Design …………………………………………………………… …………... ………… ………………………… ……………… ……….. 55 
 11.4 Analysis …………… ................................ ................................ ................................ ................................ ................................ ........ 56 
 11.5  Expected Accrual Rate, Accrual Duration, and Total Study Duration  ................................ ................................  57 
12. REGULATORY AND PROTE CTION OF HUMAN SUBJE CTS  ................................ ................................ ..................  57 
ESK981  2017 -065  
Karmanos Cancer Institute   
Esanik  Therapeutics Inc.                                                   Page 5 of 67                                            Version date: 7/2/201 9
   
  12.1 Roles and Responsibilities  ................................ ................................ ................................ ................................ .....................  57 
 12.2 Ethical Considerations  ................................ ................................ ................................ ................................ ............................  57 
 12.3 Written Informed Consent  ................................ ................................ ................................ ................................ ....................  57 
 12.4 Protection of Privacy  ................................ ................................ ................................ ................................ ................................  58 
 12.5 Terminating or Modifying the Study  ................................ ................................ ................................ ................................ . 58 
13. REFERENCES  ................................ ................................ ................................ ................................ ................................ ..... 59 
APPENDIX A: PERFORMA NCE STATUS CRITERIA  ................................ ................................ ................................ ....... 60 
APPENDIX B: MEDICATI ONS WITH THE POTENTI AL FOR DRUG -DRUG INTERACTION ..……………......…….61 
APPENDIX C:  STUDY CALENDAR  ................................ ................................ ................................ ................................ ....... 63 
APPENDIX D:  GLOSSARY OF ABBREVIA TIONS AND ACRONYMS ................................ ................................ ............  64 
APPENDIX  E. PI[INVESTIGATOR_142990]  ................................ ................................ ................................ ................................ .....................  66 
APPENDIX F. DSM REPORT FORM  ................................ ................................ ................................ ................................ ..... 67 
  
   
ESK981  2017 -065  
Karmanos Cancer Institute   
Esanik  Therapeutics Inc.                                                   Page 6 of 67                                            Version date: 7/2/[ADDRESS_1137309] categorized as a series of 
clinical states defined by [CONTACT_820659], the presence or absence of 
distant disease (metastatic vers us non -metastatic), testosterone levels, and the lines of 
therapy a patient has received (Figure 1).3 These clinical states involve the complex 
interplay of a network of signaling molecules that collectively promote net cell  
proliferation relative to cell death. The clinical states model aligns with the indications 
and uses of currently approved drugs and provides a framework for a decision tree that 
closely follows contemporary clinical practice . 
Figure 1. Clinical states of prostate cancer  
 
Although advanced prostate cancer usually responds to therapi[INVESTIGATOR_820613] -
axis signaling, resistance inevitably develops, leading to the emergence of castration -
resistant prostat e cancer (CRPC). Importantly, the clinical efficacy of novel therapi[INVESTIGATOR_820614] (AR) signaling, such as abiraterone and enzalutamide, have 
confirmed that most CRPC remains AR signaling intact.4-6 Since resistance to these 
therapi[INVESTIGATOR_820615], approaches to improve the duration of response and 
address the key pathways of resistance are very much needed.  
Despi[INVESTIGATOR_820616],7 a recently presented Phase III trial 
evaluating the multi -tyros ine kinase inhibitor (MTKI) cabozantinib in CRPC did not meet 
its primary survival endpoint.8 Although the AR signaling status was unknown in trial 
participants, the majority of men with CRPC retain active AR signaling.9,10 Our preclinical 
study provided a mechanistic basis and rationale of combining cabozantibib with 
enzalutamide to co -target the MET kinase and AR respectively and, furthermore, provided 
a potential explanation for the failure of cabozantinib monotherapy in the pi[INVESTIGATOR_820617].11 
In a search for alternate M TKIs that could be re -positioned for the treatment of metastatic 
CRPC (mCRPC) , we synthesized and evaluated ESK981 amongst a panel of other MTKIs. 
Interestingly, as our preliminary data will highlight, ESK981 exhibited nanomolar activity 
in the inhibition of prostate cancer cell line growth relative to other MTKIs tested including 
cabozantinib and crizotinib (both of which have been evaluated clinically in mCRPC). These 
early results pi[INVESTIGATOR_820618] -fold 
increased sensitivity to ESK981 relative to other MTKIs in prostate cancer cells.   

ESK981  2017 -065  
Karmanos Cancer Institute   
Esanik  Therapeutics Inc.                                                   Page 7 of 67                                            Version date: 7/2/201 9
   
 ESK981 is an orally active multiplex kinase inhibitor with favorable safety, pharmaceutical, 
ADME (absorption, distribution, metabolism, and excretion), and pharmacok inetic profiles. 
Clinical testing demonstrated linear dose -related oral exposure in humans with [ADDRESS_1137310] ivity in kinases 
implicated in angiogenesis including vascular endothelial growth factor receptor 1 
(VEGFR -1), VEGFR -2, and Tie -2, (IC50 of 3, 4, 22nM, respectively). ESK981 treatment 
potently inhibited HUVEC capi[INVESTIGATOR_820619] t angiogenesis in 
vitro , and inflammation -induced angiogenesis in Tucker mice and several VEGF -induced 
angiogenesis models in vivo . ESK981 was tested in a dose -escalating Phase I clinical trial to 
determine its pharmacokinetics and pharmacodynamics in pati ents with advanced, 
relapsed, or refractory solid tumors .13 ESK981 was acceptably tolerated up to a dose of 
97.4 mg/m2 (maximum tolerated dose) that was determined to be the recommended 
Phase II dose. Most a dverse events were G rade 1 or Grade 2 and included fatigue,  nausea, 
diarrhea, decreased appetite, abdominal pain, back pain, vomiting, constipation, headache, 
dizziness, and dyspnea. Grade 3/[ADDRESS_1137311] -dose cohorts.  
More importantly, up to 85% of patients achieved stable disease when  measured at ≥6 
weeks in cohorts receiving ≥73.0 mg/m2.   
Figure 2. Kinases overexpressed in mCRPC (in red) and 
their in vitro  inhibition with 25 nM ESK981 (blue).  
Log-fold change of kinases in mCRPC relative to benign prostate 
assessed from a compendia of RNA -seq data. Rank ordered 
inhibition profile of 25 nM ESK981 dete rmined in in vitro  kinase 
assays. Intensity of color is associated with log -fold change or 
inhibitory activity.  
 

ESK981  2017 -065  
Karmanos Cancer Institute   
Esanik  Therapeutics Inc.                                                   Page 8 of 67                                            Version date: 7/2/201 9
   
 After Cephalon was acquired by [CONTACT_820660], further development of the compound was halted 
due to TEVA’s decision to discontinue internal oncology drug development and focus on 
other therapeutic areas. Due to the exciting data seen in pre -clinical prostate cancer 
models highlighted in this proposal, Esanik Therapeutics (in which [CONTACT_43913] serves 
on the Scientific Advisory Board) acquired the rights to develop ESK981 in prostate cancer 
and other indicati ons. To better understand the mechanism of action in prostate cancer, 
the kinase screen was repeated with modern kinase assays and lower drug concentrations, 
identifying novel mutant oncogenic kinases inhibited by [CONTACT_820661]981 at single digit nanomolar 
potency.  The new screen also confirmed the potency of ESK981 against TKs involved in 
angiogenesis , as well as a number of other kinases involved in cancer processes including 
PDGFRA, PDGFRB, RET, FGFR1, FGFR2, AURKA, and AURKB , among others (IC50 of 43, 12, 
9, 92,  80, 12, and 17nM, respectively). We carried out a preliminary analysis of the top 
kinases overexpressed (by [CONTACT_16638] -seq) in mCRPC and kinases most inhibited by [CONTACT_820661]981 to 
provide leads to identify the kinase target in mCRPC ( Figure 2). Importantly, as our 
preliminary data will cover, ESK981, at nanomolar levels, induces robust vacuolization 
associated with activation of the autophagy pathway suggesting that a kinase invol ved in 
this pathway was being inhibited. Other MTKIs, 
such as cabozantib and crizotinib, did not have this 
autophagic vacuolization effect even at high 
micromolar concentrations. In vitro  data also 
suggested combined effects with enzalutamide and 
continued  sensitivity in enzalutamide -resistant cell 
lines. Interestingly, in addition to AR+ prostate 
cancer cell lines, AR - prostate cancer cell lines 
were similarly sensitive to ESK981 intimating its 
potential use in small cell/neuroendocrine variants 
of prostat e cancer. In vivo , ESK981 monotherapy 
inhibited castrated VCaP xenograft growth in a 
dose -dependent fashion. Tumors from mice 
treated with ESK981 displayed vacuolization 
associated with autophagy as well as marked 
decreases in proliferation (by [CONTACT_15915]67 staini ng). 
Interestingly, autophagy is an evolutionarily 
conserved and orderly process of degradation and 
destruction of cellular components ( Figure 3). As 
part of this process, double membraned vesicles 
known as autophagosomes are formed by 
[CONTACT_820662], which then 
fuse with lysosomes to initiate degradation and 
recyc ling.[ADDRESS_1137312], has been 
found in 40 to 75% of human breast, prostate, and  
ovarian can cers.1,[ADDRESS_1137313] is the 
key proximal kinase complex that controls autophagy. It 
can be regulated by a number of up -stream kinases 
includi ng receptor tyrosine kinase (RTKs), PI3K, AKT, and 
TOR. The beclin1 complex is a mediator of autophagy. LC3 
processing is a key step in autophagosome maturation. 
Chloroquine and Bafilomycin A1 block late stage 
autophagy by [CONTACT_820663]. ESK981  
presumably activates autophagy in CRPC by [CONTACT_820664].  
 
 
 

ESK981  2017 -065  
Karmanos Cancer Institute   
Esanik  Therapeutics Inc.                                                   Page 9 of 67                                            Version date: 7/2/201 9
   
 1.2.1   Description and mechanism of action  
Nonclinical activity  
ESK981  is an orally active inhibitor of a number of receptor tyrosine kinases, specifically 
human TIE -2, VEGFR -1 and VEGF R-2, and FGFR -1, with concentration s resulting in  50% 
inhibition of activity  (IC 50) of 22±6  nM, 4±1  nM, 3±1  nM, and 13±[ADDRESS_1137314] a number of other kinases including tropomyosin receptor kinase ( TRK ) A 
(3 nM), TRKB (5 nM), receptor tyrosi ne kinase (RET) (5  nM), B lymphocyte kinase ( BLK ) 
(8 nM), hemopoietic cell kinase ( HCK ) (13  nM), lymphocyte -specific protein tyrosine 
kinase ( LCK ) (12  nM), TGF -ß activated kinase 1 ( TAK1 ) (14  nM), and mammalian STE20 -
like kinase 2  (MST2) (21  nM). Some of t hese kinases are also known to be involved in 
tumor growth and survival. ESK981  demonstrates a significant concentration -related 
activity in a range of experimental systems including VEGF -A, -C, -D-induced, 
Angiopoietin -1-induced, and  fibroblast growth fac tor-2 (FGF2 )-induced human and murine 
endothelial cell proliferation , chemotaxis, migration, and survival in vitro ; and microvessel 
outgrowth and branching in primary rat aortic ring explant cultures ex vivo . 
Preclinical studies  
Significant oral anti -angiogenic efficacy has been observed in VEGF -A-induced, 
tumor -induced and inflammation -induced neo -vascularization models in rodents.  
Sustained dose -related anti -tumor activity has been demonstrated with ESK981  in vitro  
across a panel of human and murine  tumor cell lines. Significant dose -related and exposure 
driven in vivo  anti -tumor efficacy is observed with ESK981  in multiple subcutaneous 
(melanoma, glioblastoma, breast carcinoma, prostate carcinoma) and orthotopic human 
and rodent solid (colon carcino ma, renal carcinoma, and glioblastoma) and hematologic 
(acute leukemia) tumor xenograft models in normal and immunocompromised hosts. 
Depending upon tumor models with differing dosing regimens, ESK981  exhibits 
dose -related tumor growth inhibitory and anti -angiogenic effects as well as sustained 
partial and complete tumor regressions when administered as monotherapy. Specific 
intermittent oral dosing schedules (drug dosing/drug holidays) of ESK981  using once daily 
(qd) and twice daily (bid) dosing regimens d emonstrate significant anti -tumor efficacy 
(tumor growth inhibition and partial and complete regressions). In both solid and 
hematologic tumor models, however, qd and bid continuous administration are optimal. 
ESK981  is generally well tolerated when admini stered chronically with cytotoxic agents 
(e.g., temozol omide [TMZ ]) and the combination of ESK981  with TMZ conferred a 
significant benefit on median survival of orthotopic human glioblastoma -bearing animals 
relative to that achieved with TM Z alone. In a se ries of pharmacologic anti -tumor and 
anti -angiogenic studies conducted in various murine strains, the maximum tolerated dose 
of ESK981  is 60 mg/kg/day  or higher in syngeneic, nude, and severe immunocompromised 
mice (SCID) mice, and 30  mg/kg/day or higher i n non obese diabetic/severe 
immunocompromised mice  (NOD -SCID) severely immunocompromised tumor -bearing 
mice .   
Phase I open -label, dose -escalating study  pharmacokinetics  
ESK981  was tested in a n open -label dose -escalating P hase 1 clinical trial to determine its 
pharmacokinetics  (PK)  and pharmacodynamics  (PD)  in patients with advanced, relapsed, 
or refractory solid tumors  (Study C11981/1047/ON/US, [STUDY_ID_REMOVED] ).13 After daily oral 
ESK981  2017 -065  
Karmanos Cancer Institute   
Esanik  Therapeutics Inc.                                                   Page 10 of 67                                            Version date: 7/2/201 9
   
 administration of E SK981 to cancer patients, the median t max 
values for E SK981 were 
typi[INVESTIGATOR_4942] 2 to 4 hr. (Table 1 and Table  2); however, for most of the dose 
groups there appeared to be considerable inter -patient variability in this pharmacokinetic 
parameter . The reason(s) for the large inter -patient variability in tmax 
is (are) not presently 
known, but may be related to the fed/fasted state of the patients or other unknown factors 
which could potentially influence drug absorption (e.g., disease state, concomitant 
medications).  
Table 1. Mean (SD) Pharmacokinetic Parameters  for SK981 in Cancer Patients on Day 1 of Daily Oral 
Administration of ESK981  
 
Table 2. Mean (SD) Pharmacokinetic Parameters for ESK981 in Cancer Patients on Day 15 of Daily Oral 
Administration of ESK981  
 
After reaching peak plasma levels, E SK981 declined in a bi -phasic manner that was 
characterized by [CONTACT_820665] a slower terminal elimination 
phase . For some profiles, however, only the later phase was evident due to what appeared 
to be a more prolonged period of drug absorption. The mean t 1/2 
of the terminal 
elimination phase was generally in the range of appro ximately 8 to 10 hr; however, the 

ESK981  2017 -065  
Karmanos Cancer Institute   
Esanik  Therapeutics Inc.                                                   Page 11 of 67                                            Version date: 7/2/201 9
   
 values tended to be slightly larger after multiple doses at the higher dose levels (i.e., doses 
≥55 mg/m2) (Table 1 and Table 2).  
The systemic exposures (i.e., C max 
and AUC) of patients to ESK981 generally increased with 
increasing dose across the dose range evaluated on both days 1 and 15 ( Table 1 and Table 
2). There were some dose groups for which the mean values of C max 
and AUC did not show 
an increase relative to the values from the preceding 1 or 2 dose levels; however, this 
result was n ot surprising given the large inter -patient variability and the fact that most 
dose increments were less than 40%. Nonetheless, the overall results obtained are not 
suggestive of the presence of any obvious non -linearity in absorption and/or elimination of  
ESK981 in this dose range.  
After once -daily administration of E SK981 at doses ranging from 3.0 to 126.6 mg/m2, there 
was a small to moderate amount of accumulation of the compound in plasma at each dose 
level. The overall mean observed accumulation ratio  (Robs) for E SK981 was 1.5 (range = 1.1 
to 1.9), which was slightly larger than the value predicted from the single -dose data 
(overall mean R pred 
= 1.2; range = 1.0 to 1.3) ( Table 1 and Table 2). Although the mean R obs 
was slightly larger than the R pred, this is not believed to be a strong indication  of the 
presence of any time -dependent pharmacokinetic processes.  
1.2.2  Clinical safety and efficacy  
Adverse events  
All 43 patients experienced ≥1 adverse event, and 38 patients (88.3 %) were deemed to 
have had adverse events possibly, probably, or definitely related to study drug. The most 
frequently reported adverse event of any grade was fatigue (n= 22, or 51 %). Other 
frequently reported adverse events (≥20 % of patients) were nausea (47 %), diarrhea (33 
%), decreased appetite (33 %), abdominal p ain (30 %), back pain (28 %), vomiting (28 %), 
constipation (28 %), headache (28 %), dizziness (28 %), and dyspnea (23 %). These 
adverse events were reported at a similar frequency between dosage cohorts, and no 
relationship with dose was evi dent. Most adv erse events were G rade 1 or Grade 2.  
Grade 3 or 4 adverse events occurred in 16 (37 %) patients across dosing cohorts (14 [32.6 
%] Grade 3 and 2 [4.7 %] Grade 4). Treatment -related Grade [ADDRESS_1137315] frequent in the 97.4 mg/ m2 cohort. G rade 3 or 4 laboratory hematologic toxicities 
were reported in 8 (18.6 %) patients across dosage cohorts. The most common Grade 3 or 
4 laboratory hematologic toxicity was lymphopenia, which occurred in 8 patients and 
across dosage cohorts (5.9, 29.6, 55.0,  97.4, and 126.6 mg/m2). Grade 4 leukopenia 
occurred in 1 patient in the 126.6 mg/ m2 cohort. Grade 3 or Grade 4 neutropenia also 
occurred in 2 patients in the 97.4 mg/ m2 cohort (Grade 3) and in 1 patient in the 126.6 
mg/m2 cohort (Grade 4).  
Serious adverse events occurred in 12 patients; most were deemed unlikely or not related 
to ESK981 . Three patients (1 patient in the 97.4 mg/m2 cohort and 2 patients in the 126.6 
mg/m2 cohort) experienced serious adverse events that were categorized as pos sibly or 
definitely related to ESK981 : pyrexia, hemolytic a nemia, hyperbilirubinemia, dys pnea, 
neutropenia, ECG change, and chest discomfort. No deaths occurred during the study.  
One patient with an unrelated serious adverse event was a 76 -year -old white man with 
metastatic prostate cancer. He started open -label treatment with CEP -[ZIP_CODE] on 21 January 
2010. He had a history of being heavily pretreated with bicalutamide, leuprolide, 
ketoconazole, GVAX vaccine, CNTO, docetaxel, cyclophosphamide, mitoxantrone,  and 
several other agents in clinical trials.  Relevant medical history included lumbar 
ESK981  2017 -065  
Karmanos Cancer Institute   
Esanik  Therapeutics Inc.                                                   Page 12 of 67                                            Version date: 7/2/201 9
   
 laminectomies, osteoarthritis, lower back pain, pelvic pain, and intermittent right hand 
crampi[INVESTIGATOR_007]. On 04 February 2010 (day 15), the patient had an elevated creatine 
phosphokinase laboratory value of 241 U/L (normal range, 25 -195 U/L); study drug was 
interrupted from 05 -10 February 2010. The laboratory value was back to normal at 165 
U/L on 09 March 2010 (day 48).  
The last dose of study drug was administered  on 23 February 2010 (day 34). On 25 
February 2010 (day 36), the patient experienced serious adverse events of back pain, 
musculoskeletal pain, and abdominal pain, all Grade [ADDRESS_1137316] nous dexamethasone and morphine. 
The patient was hospi[INVESTIGATOR_820620] a magnetic resonance imaging (MRI) 
scan of the thoracic spi[INVESTIGATOR_820621]. The MRI scan was negative for 
cord compression. All 3 serious adverse events reso lved on day 37, with residual effects, 
and the patient was discharged from the hospi[INVESTIGATOR_307]. The investigator considered the serious 
adverse events of back pain, musculoskeletal pain, and abdominal pain unlikely related to 
the study drug. The patient was withd rawn from the study on 09 March 2010 (day 48) 
because of disease progression.  
Another patient with  experienced pyrexia, hemolytic anemia, and hyperbilirubinemia.  The 
patient was a [ADDRESS_1137317] 2010 (day 6), the patient was hospi[INVESTIGATOR_779185] 3 serious  adverse events of 
pyrexia (102°F), hyperbilirubinemia, and hemolytic anemia. She also  had a urinary tract 
infection, pain in bilateral lower extremities, blurry vision, sinus  tachycardia, l ethargy and 
thrush. The study drug was held during admission. The  patient's laboratory tests 
performed on days 6 and 7 showed an elevated bilirubin at  5.2 mg/dL and hemoglobin at 
9.6 g/dL, a concern for hemolytic anemia; the patient's  haptoglobin was 315 m g/dL.  
Blood cultures were negative, but the urine culture was  positive for E. coli . The patient was 
treated with ciprofloxacin for the urinary tract  infection and fluconazole for thrush. On 02 
September 2010 (day 9), the patient's blood  lactate dehydrogen ase (LDH) was 618 U/L. 
The events of pyrexia and  hyperbilirubinemia resolved by [CONTACT_4475] 10, with a temperature of 
97.1°F, total bilirubin of  1.3 mg/dL and a hemoglobin of 10.6 mg/dL. The patient did not 
require a transfusion,  and her bilirubin, hemoglobin, and  hematocrit resolved during 
hospi[INVESTIGATOR_059]. The  patient was discharged from the hospi[INVESTIGATOR_607815] 9 (data on file). The 
investigator  considered the serious events of pyrexia, hemolytic anemia, and 
hyperbilirubinemia as  possibly related to the study drug. On  08 September 2010 (day 15), 
the patient had  Grade 3 serious adverse events of nausea and vomiting that required 
hospi[INVESTIGATOR_059]. An  x-ray of the kidneys, ureters, and bladder was negative for obstruction 
or ileus, but  indicated constipation. Her constipat ion was treated with docusate/senna, 
which  improved the nausea and vomiting. The investigator considered the serious adverse  
events of nausea and vomiting, which resolved on 10 September 2010 (day 17), to be not  
related to the study drug. The last dose of study drug administered was on  [ADDRESS_1137318] 2010 
(day 5). The patient was withdrawn from the study on  08 September 2010 (day 15) 
because of the serious adverse events of pyrexia, hemolytic  anemia, and 
hyperbilirubinemia.  
Another patient experienced dyspnea, electrocardiogram changes, chest discomfort.  The 
patient was a 57 year -old white woman with colorectal cancer. She started  open -label 
treatment with CEP -[ZIP_CODE] on 08 December 2010. On 15 December 2010 (day 8), the 
ESK981  2017 -065  
Karmanos Cancer Institute   
Esanik  Therapeutics Inc.                                                   Page 13 of 67                                            Version date: 7/2/201 9
   
 patie nt experienced serious adverse events of dyspnea (Grade 2), electrocardiogram (EKG) 
change (Grade 3), and chest discomfort (Grade 2). The EKG showed a t -wave inversion that 
was not present on previous EKGs. She was subsequently hospi[INVESTIGATOR_820622] 
(data on file). The last dose of study drug was administered on 14 December 2010 (day 7). 
The events of EKG change and chest discomfort resolved with no residual effects on 20 
December 2010 (day 13). The event of dyspnea did not resolve. On 29 December  2010 
(day 22), the patient had a nonserious adverse event of Grade [ADDRESS_1137319] discomfort to be possibly related to the study drug.  
In the Phase I study, 19/43  patients  received more than 28 days (range 33 -504 days)  of 
treatment . Table 3 provides the patient’s dose level, number of days on treatment, and 
adverse events reported.   There were no Grade [ADDRESS_1137320] one Grade 3 toxicity.  
ESK981  2017 -065  
Karmanos Cancer Institute   
Esanik  Therapeutics Inc.                                                   Page 14 of 67                                            Version date: 7/2/201 9
   
 Table 3. Adverse Events Occurring On or After Day 28 in P atients that Received more than 
28 days of Treatme nt
 
 
 
 
  
Pts treated >27 
daysDays on 
Treatmen
tDose 
(mg/m2
)Grade 1 Grade 2 Grade 3
001002/K-M 110 3.0Dry skin, Nausea, Sinus headache, Gamma-
glutamyltransferase increased, Abdominal tenderness, 
Hypercalcaemia, Blood lactate dehydrogenase increased Hyperglycaemia, Vulvovaginal pruritus, Fatigue Abdominal pain
001001/RAM 322 3.0Rhinitis, Wheezing, Hypoalbuminaemia, Nasopharyngitis, 
Sinus headache, Gamma-glutamyltransferase increased, 
Dyspnoea, Nausea, Oedema peripheral, Hypokalaemia, 
Burning sensation, Hyperglycaemia, Headache, 
Hypercholesterolaemia, Blood creatine phosphokinase 
increased, Vomiting, Pain in extremity, Hypoglycaemia, 
Blood creatinine increased, Back painAbdominal pain, Fatigue 
002003/CEC 69 4.2Hyperkalaemia, Wheezing, Dyspnoea, Oral discomfort, 
Blood alkaline phosphatase increased, Constipation, 
Decreased appetite, Tachycardia, Oedema peripheral, 
Hyperglycaemia 
002005/DNH [ADDRESS_1137321] 
discomfort, Asthenia, Hyperhidrosis Fatigue, Nocturia Hyperkalaemia
002008/DLH 70 11.8Groin Pain, Decreased appetite, Nasopharyngitis, Myalgia, 
Hyperuricaemia, Urinary incontinence, Haemoglobin 
decreasedHyperglycaemia, Neuropathy peripheral, Tongue 
ulceration 
002009/RMH 70 19.7Hot flush, Gastrooesophageal reflux disease, 
Rhinorrhoea, Fatigue, Eye pain  
001015/SRG [ADDRESS_1137322] infection, 
Hyponatraemia, Oedema peripheral, Erythema, Cough, 
Dyspnoea, International normalised ratio increased, 
Proteinuria Ureteric obstruction, Abdominal pain, Proteinuria 
001017/D-F 41 29.6 None (All AEs had onset before day 28),  
003002/MAR 90 29.6 Decreased appetite Anaemia, Myocardial ischaemia 
002010/EJB 217 29.6Hypoaesthesia, Lip pain, Colonic polyp, Dry skin, Nausea, 
Decreased appetite, Asthenia, Constipation Cough 
002011/KJD [ADDRESS_1137323] infection 
002014/CSS 33 55.0 Decreased appetite Fatigue, Oedema peripheral Back pain, Musculoskeletal pain, Abdominal pain, Scrotal 
oedema
001018/ADM [ADDRESS_1137324] infection, 
Hyperuricaemia, Abdominal pain, Decreased appetite, 
Mood swings Pain in extremity, Presyncope, Mucosal inflammation, 
Blood bilirubin increased 
003003/MLK [ADDRESS_1137325] infection Somnolence, Arthralgia, Anxiety, Impaired healing, 
Cellulitis, Oedema peripheral,
001021/JBR [ADDRESS_1137326] infection, 
Weight descreased, Tachycardia, Dehydration, Back pain, 
Flank pain, Oedema peripheral, VomitingHeadache, Neck pain, Diarrhea, Decreased appetite, 
Anemia, Musculoskeletal pain,
001022/EDM [ADDRESS_1137327] pain, Pain in extremity  
001025/VGY 76 97.4 Neuropathy peripheral, Flank pain, Contusion, Insomnia  
002017/RWF 127 97.4 Rhinorrhoea, Pulmonary mass, Diarrhoea, Dysphonia  
002018/CRC [ADDRESS_1137328] congestion, 
Decreased appetite, Diarrhoea, InsomniaCough, Pneumonia Chronic obstructive pulmonary disease
ESK981  2017 -065  
Karmanos Cancer Institute   
Esanik  Therapeutics Inc.                                                   Page 15 of 67                                            Version date: 7/2/201 9
   
 Tumor response  
Out of 43 patients who received ≥[ADDRESS_1137329] criteria, 19 of 37 (51 %) patients evaluated for tumor response had stable 
disease at ≥6 weeks; 18 had disease progression. The frequency of stable dise ase (defined 
as <30 % decrease and <20 % increase in the sum of the longest diameter of the target 
lesions) was higher in cohorts receiving doses ≥73.0 mg/m2 (8 of 14 [57.1 %] patients) 
compared with cohorts receiving ≤55.0 mg/m2 (11 of 29 [37.9 %] patient s) (Figure 4 ).  
 
 
Figure 4.  
Best overall tumor response per cohorta at >/= 6 weeks . Depi[INVESTIGATOR_820623], with bars above the x -
axis indicating patients (n = 19) who achieved stable disease and bars below the x -axis indicating patients 
(n = 18) with disease progression. aNo patient achieved complete or partial response. bSix patients were 
not evaluable at dosages of 19.7, 29.6, 55.0, an d 126.6 mg/m2 (n = 1, each); 97.4 mg/m2 (n = 2)  
 
 
1.3   Rationale  
ESK981 has cleared a dose -escalating Phase I clinical trial and demonstrated favorable 
pharmacokinetics and pharmacodynamics in patients with advanced, relapsed, or 
refractory solid tumors with up to 85% of patients achieving stable disease at doses 
≥73.0 mg/m2. In our preliminary studies, ESK981 appears to induce robust 
vacuolization associated with activation of the autophagy pathway in prostate cancer 
in vitro  and in vivo  and demonstrated dose -dependent inhibition of castrated VCaP 
xenograft growth ( Figure 5).  

ESK981  2017 -065  
Karmanos Cancer Institute   
Esanik  Therapeutics Inc.                                                   Page 16 of 67                                            Version date: 7/2/201 9
   
 Figure 5.  
ESK981 inhibits castrate d VCaP tumor growth.  Castrated VCaP -bearing mice received vehicle or ESK981 
(60 or 30mg/kg) as indicated. A, Tumor volume was measured twice per week over a [ADDRESS_1137330] progressed on 
enzalutamide and/or abiraterone acetate. Consenting patients will undergo a biopsy at 
baseline and after 8 weeks of t reatment to assess gene expressi on and biomarkers. The 
primary objective will be to determine the PSA ≥ 50% response rate (PSA50) from 
baseline using the  Prostate Cancer Working Group 3 ( PCWG3 ) criteria to ESK981 as a 
single agent.  
Currently, CRPC patient s receive either enzalutamide or abiraterone acetate as front -
line treatment for mCRPC without visceral metastases. If a patient has metastatic 
disease with visceral metastases he may also receive chemotherapy such as docetaxel. 
This study explore s if ESK9 81, administered 5 days on and 2 days off can induce a high 
PSA response rate and/or if AR expression is induced or enhanced from baseline 
following a standard front -line treatment to  determine the PSA50 response rate to 
ESK981.  
1.[ADDRESS_1137331] cellular vacuolization. Thus, 
autophagy can serve a s biomarker for patient response to ESK981 treatment.  
1.4.2  Angiogenesis inhibition  
Considering ESK981’s anti -VEGFR-A property and our in vivo  preliminary data that 
ESK981 strongly attenuated angiogenesis, we believe that angiogenesis can be a 
biomarker fo r patient response to ESK981 treatment.  
1.4.[ADDRESS_1137332] been validated in our preliminary in vitro  models. Using 
immunohistochemistry (IHC) to determine phosphorylation levels of these targets can 
help to assess ESK981 pharmacodynamic s in patient.   
 

ESK981  2017 -065  
Karmanos Cancer Institute   
Esanik  Therapeutics Inc.                                                   Page 17 of 67                                            Version date: 7/2/[ADDRESS_1137333] shown that ESK981 significantly inhibited  tumor cell 
proliferation in vitro  and in vivo  xenografts . Therefore, we believe that determin ing 
proliferation rate by [CONTACT_15915]67 IHC will also be a potential biomarker for patient response to 
ESK981 treatment.  
1.4.5  Other potential markers  
Overall  patient survival, assessment by [CONTACT_485622], radiographic progression free 
survival, and PSA  progression free survival can be monitored clinically as surrogates 
for treatment outcomes. Mutation analysis by [CONTACT_136922], 
immunohistochemistry to quantify PD -1 and PD -L1 expression and presence of CD8+ 
tumor infiltrating lymphocytes can be useful in exploratory evaluation.  In addition, 
select genetic and epi[INVESTIGATOR_820624]’ tumors will be assessed as 
surrogate biomarkers for clinical benefit. These evaluations are expected to identify 
genomic correlates of response (biochemical recurrence, onset of pain), complications 
(osteoblastic lesions in bone, cachexia), and survival. The specific biomarker 
candidates were identified bas ed on their inclusion in either of the following 
actionable/informative categories: (i) immediate link with the ESK981 mechanism of 
action, (ii) high prevalence in mCRPC and/or routine clinical testing, (iii) potential less -
invasive detection in biofluids.  Respectively, the proposed correlative endpoints 
include expression levels of ESK981 target kinases, ETS -status, and AR 
amplification/levels in circulating tumor cells. The rationale for each biomarker choice 
and correlative asses sment is listed in sectio n 1.4, while methodological and statistical 
considerations for the genomic scree ning are reviewed in section  11.3 . 
2.  OBJECTIVES  
2.1 Primary Objective  
The primary objectives of this study are:  
 To determine the PSA ≥ 50% response rate (PSA5 0) from baseline using the 
PCWG3 criteria to ESK981  as a single agent in men wi th mCRPC who have 
progressed on e nzalutamide (an oral andro gen-receptor inhibitor) and/or oral 
abiraterone acetate (an androgen synthesis inhibitor).  
 To a ssess the safety and to lerability of ESK981  as a single agent. Adverse events of 
all grades will be captured by [CONTACT_29630] - Common 
Terminology Criteria for Adverse Events, version 4.03 (NCI -CTCAE v4.03) and GCP 
standards.  
2.2 Secondary Objectives  
 To determin e the time to PSA response to ESK981 in mCRPC patients . 
 To determine the duration of PSA response to ESK981 in mCRPC patients.  
 To determine PSA progression rates as defined by [CONTACT_338532]3  criteria.  
 To determine PSA progression free survival as defined by [CONTACT_338532]3 criteria  
ESK981  2017 -065  
Karmanos Cancer Institute   
Esanik  Therapeutics Inc.                                                   Page 18 of 67                                            Version date: 7/2/201 9
   
 2.3 Correlative/ Exploratory/ Tertiary Objectives  
 To assess exploratory biomarkers from blood and tumor biopsies. Examples of 
these may include, but are not limited to: whole exome sequencing, capture 
whole transcriptome analysis, AR and A Rv7 analysis, ki -67, apoptosis, etc.  
3. PATIENT SELECTION  
A total of [ADDRESS_1137334] (IRB)/ Independent 
Ethics Committee (IEC) -approved conse nt form and written authorization to use 
protected health information as outlined in the Health Insurance Portability Act 
(HIPAA) of 1996, prior to the initiation of any study related procedures.   
3.1 Inclusion Criteria  
Patients should meet all of the foll owing criteria at the time of registration:  
3.1.[ADDRESS_1137335] understands the 
purpose of and procedures required for the study and are willing to participate in the 
study.  
3.1.2 Be willin g and able to adhere to  the prohibitions and restrictions specified in this 
protocol.  
3.1.3 Males  18 years of age and above.  
3.1.4 Eastern Cooperative Group (ECOG) performance status ≤1.  
3.1.[ADDRESS_1137336] progressive disease while receiving androgen deprivation therapy 
(ADT) defined by [CONTACT_820666]3 criteria for PSA, 
measureable or non -measurable (bone) disease and must have a castrate serum 
testosterone level (i.e. ≤ 50 ng/dL) at screening :  
[IP_ADDRESS]  PSA: At least two consecutive rises in serum PSA, obtained at a 
minimum of 1 -week intervals, with the final value ≥ 2.0 ng/mL.  
[IP_ADDRESS]  Measurable disease (by [CONTACT_393] 1.1): ≥20% increase  (with an 
absolute increase of at least 5mm)  in the sum of  diameters of all 
mea surable lesions or the development of one or more new lesions. 
The short axis of a target lymph node must be more than 15mm to 
be assessed for change in size.  
[IP_ADDRESS]  Non -measurable (bone) disease: The appearance  of two or more 
new areas of uptake on bone scan con sistent with metastatic 
disease compared to previous imaging during castration therapy. 
The increased uptake of pre -existing lesions on bone scan will not 
be taken to constitute progression, and ambiguous results must be 
confirmed by [CONTACT_820667] (e.g. X -ray, CT or MRI).  
3.1.6 Documented histologically confirmed adenocarcinoma of the prostate.   
3.1.7 Metastatic prostate cancer (M1) as documented by [CONTACT_820668] (i.e. 
CT-Scan, PET scan or bone scan).  
 
ESK981  2017 -065  
Karmanos Cancer Institute   
Esanik  Therapeutics Inc.                                                   Page 19 of 67                                            Version date: 7/2/201 9
   
 3.1.8 Treatment failure of either abiraterone and/ or enzalutamide  per PCWG3 criteria  for 
PSA, measurable disease or non-measurable (bone) disease . 
 
3.1.[ADDRESS_1137337] 
dose of therapy.  
 
3.1.10  Willingness and ability to comply with study procedures and follow -up examination . 
 
3.1.11  Able to swallow and retain oral medication.  
 
3.1.12  Willingness and ability to undergo mandatory tumor biopsy at baseline  and week 
8/cycle [ADDRESS_1137338] cycle , and then monthly . 
3.2 Exclusion Criteria  
3.2.1  Current systemic therapy (other than a GnRH agonist/antagonist) for CRPC includi ng: 
a. CYP -17 inhibitors (e.g. ketoconazole, abiraterone)  
b. Antiandrogens (e.g. bicalutamide, nilutamide)  
c. Second generation antiandrogens (e.g. enzalutamide, ARN -509, Galeterone)  
d. Immunotherapy (e.g. sipuleucel -T, ipi[INVESTIGATOR_125])  
e. Chemotherapy (e.g. docetaxel, ca bazitaxel)  
3.2.2 Prior chemotherapy (e.g. docetaxel, cabazitaxel) for CRPC . Prior docetaxel 
administered in the castrate -sensitive space is allowed.  
3.2.3 Prior radiopharmaceutical therapy (e.g. radium -223, strontium -89, samarium -153, 
etc.) within the pas t year . 
3.2.[ADDRESS_1137339] from meeting or performing 
study requirements . 
3.2.5 The patient has any of the following hematologic values:  
 absolute neutrophil count (ANC) less than 1500/mm3 
 platelet count less than 100000/mm3 
 hemoglobin less than 9 g/dL.  
3.2.6 The patient has any of the following hepatic function values:  
 bilirubin greater than 1.5 times the upper limit of normal (ULN)  
 alanine aminotransferase (ALT) greater than 2.[ADDRESS_1137340]  in the absence 
of known hepatic metastases  
 aspartate aminotransferase (AST) greater than 2.[ADDRESS_1137341] in the 
absence of known hepatic metastases,  
  ALT or AST greater than 3.[ADDRESS_1137342] in the presence of known hepatic 
metastases.  
3.2.7 The patient has a serum creatinine value greater than 1.5 mg/dL.  
3.2.8 The patient has active brain  metastases.   
ESK981  2017 -065  
Karmanos Cancer Institute   
Esanik  Therapeutics Inc.                                                   Page 20 of 67                                            Version date: 7/2/[ADDRESS_1137343]’s source documents.  
4. ENROLLMENT PLAN  AND SUBJECT REGISTRA TION  
4.1 Registration Procedure  
 All patients shall be registered with the Cancer Center Clinical Trials Office at (31 3) 
576 -9837 (Kim Dobson ). At the time of registration, a pre -study form and all 
information required to verify eligibility shall be necessary on each patient prior to 
treatment.  
4.[ADDRESS_1137344] treatment.   
 The following information will be collected: The subject’s survival status, and 
if deceased, the date of death.  
 The method by [CONTACT_820669].  
 Any subsequent anti -cancer therapy received after discontinuation from 
study drug.  
 The subject will be determined to be lost to follow -up only after at least [ADDRESS_1137345] be made through certified letters.  
  
ESK981  2017 -065  
Karmanos Cancer Institute   
Esanik  Therapeutics Inc.                                                   Page 21 of 67                                            Version date: 7/2/201 9
   
 5. TREATMENT/INTERVENTI ON PLAN  
This is a n open -label, non -randomized  single -stage Phase  II design  of ESK981  in 
patients with mCRPC  who have had prior enzalutamide and/or abiraterone.  Patients  
will receive 8 weeks of ESK981, and then be evaluated for their rate of PSA decline of ≥ 
50% from baseline (PSA50), using the PCWG3 criteria.   
Assessments and procedures that will occur du ring the study  are detailed in Appendix C . 
An overall study  schema appears below:  
 
5.1 Removing Subjects  from the Protocol  
In the absence of treatment delays because of adverse events, treatment will continue 
for 8 weeks . If at the conclusion of the 8 -week period, no disease progression has 
occurred, the participant can stay on trial until one of the following criteria applies:  
5.1.[ADDRESS_1137346]  decides to withdraw from the study . 
5.1.2 Disease progression  
 symptomatic disease progression  at any time  
 objective clinical disease progression  
5.1.[ADDRESS_1137347] is no longer clinically benefitting (NLCB) from treatment . 
5.1.4 Intercurrent illness that prevents further administration of treatment . 
5.1.5 Unacceptable adverse event(s) that may or may not be directly rel ated to treatment 
but that, in the judgment of the treating physician, makes it dangerous for the subject  
to be retreated . 
5.1.6 General or specific changes in the patient’s condition that render the patient 
unacceptable for further treatment, in the judgment of  the investigator . 
q4 weeks  
PSA  
Safety labs  
Plasma  
Until  the 
end of 
treatment  PSA  [ADDRESS_1137348] 
received prior 
enzalutamide and 
/or abiraterone  
ESK981  2017 -065  
Karmanos Cancer Institute   
Esanik  Therapeutics Inc.                                                   Page 22 of 67                                            Version date: 7/2/[ADDRESS_1137349]  and to 
perform a final evaluation. The date and the specific reason(s) for withdrawal should 
be recorded.  
5.2 Definition of compliance with the self -administered oral agent ESK981  
  Based on pi[INVESTIGATOR_820625] 981 
returned  by [CONTACT_102], the % of intended ESK981  pi[INVESTIGATOR_820626].   If that % is ≥ 75% over Cycle 1 (the first 28  days of ESK981  treatment ), 
then  the patient will be deemed “complian t” with the intended oral ESK981  treatment 
regimen.  
6. THERAPEUTIC  AGENT  
6.1 Description of Treatments  
Patients will receive 160mg (4 capsules) of ESK981 dosed once daily for five 
consecutive days  followed by a two  consecutive day treatment break , for a cycle of 28 
days . Drugs can be taken in the fed or fasted state. If at the conclusion of the 8 -week 
period, no disease progression has occurred, refer to section 5.1 to determine i f 
participant can stay on trial.   
6.2 ESK981 Drug Supply and Return  
 Shipment  and Receipt  
Esanik Therapeutics, Inc  has contracted with Sharp Clinical Services Inc.  as the vendor 
for the storage and shippi[INVESTIGATOR_820627]981 (CEP11981) ; therefore, all drug shipments will 
be received from Sharp  and not directly from Esanik .  All drug shipments will be sent to 
the attention of the appropriate pharmacy contact, wh ich will be identified in advance 
by [CONTACT_820670].  This 
includes study drug receipt, accountability, storage/handling, and proper dispensation.  
Note:  The initial shipment will be at least [ADDRESS_1137350] 
enough ESK981 (CEP11981)  in stock for initial [ADDRESS_1137351] not be 
placed in the active inventory or used in the clinical trial without Esanik’s approval.   
The Pharmacy  should  open the package as soon as possible and  compare the Drug 
Shipment Form  to the contents of the shipment upon receipt. If there is a discrepancy 
between the Drug Shipment Form and the shipment contents, if bottles  arrive 
damaged, or a temperature de viation is noted from the monitoring device  (see below) , 
ESK981  2017 -065  
Karmanos Cancer Institute   
Esanik  Therapeutics Inc.                                                   Page 23 of 67                                            Version date: 7/2/[ADDRESS_1137352] Esanik 
immediately for further instruction.  
All shipments will arrive in insulated shippers at approximately 2 -8°C, and will i nclude 
a temperature monitoring device to verify temperature during transit. Upon receipt of 
the shipment, please follow the steps below as expeditiously as possible:  
1. Open the package, locate temperature log device.  
2. Follow the instructions provided to review the temperature tracking.  
3. If a temperature deviation is noted, please contact [CONTACT_820671].  
4. If no temperature deviations are noted,  the study drug may be accepted into 
the active inventory.  
Storage  
Upon acceptance , ESK981  must be immediately removed from  the shippi[INVESTIGATOR_820628] 2 -8C. The storage temperature should be monitored and 
recorded daily to ensure temperatures are maintained at 2 -8C. A temperature log is 
provided in Attachment 1; however, sites may use their own temperatur e log or the 
one provided in this manual.  Sites unable to record daily temperatures must provide 
verification that there are no temperature deviations.   
ESK981 must be kept in a secure place with limited access under the appropriate 
storage conditions  at all times . All personnel involved in the dispensing of 
investigational product should be aware of its locati on. Any deviations in 
accountability and/or storage  should be reported to Esanik . 
Resupply of Investigational Product  
All investigational product re supply requests should be made by [CONTACT_494214] e -mailing 
the Site Investigational Drug Shippi[INVESTIGATOR_820629] (Attachment 2) your CRA or 
designee . A minimum of two weeks (10 business days) is required for routine 
resupply;  therefore, pharmacies are encouraged to proactively manage drug inventory 
to avoid supply problems.    
Drug Return  
At the conclusion of the study, the pharmacy will receive specific instructions on how 
to handle any undispensed investigational product. Pharmacists are not to return or 
destroy any unused investigational product until these instructions are received.    
6.[ADDRESS_1137353] Esanik  Therapeutics, 
Inc. before the destruction of any records pertaining to the study to ensure they no 
longer need to be retained.   
Study related forms located in the Attachment Section of this manual should be 
completed using p ermanent black ink only. Any error should be crossed through with a 
single pen stroke, initialed and dated. Do not attempt to cover up an error by 
[CONTACT_820661]981  2017 -065  
Karmanos Cancer Institute   
Esanik  Therapeutics Inc.                                                   Page 24 of 67                                            Version date: 7/2/[ADDRESS_1137354]  
Pharmacies may use institutional forms and systems for managing inventory and 
accountability provided they meet regulatory requirements for investigational agents . 
A log entry is made eac h time ESK981  is received and dispensed by [CONTACT_779].      
Attachments  
Attachment 1: Temperature Monitor Log  
Attachment 2: Site Investigational Drug Shippi[INVESTIGATOR_820630]981  2017 -065  
Karmanos Cancer Institute   
Esanik  Therapeutics Inc.                                                   Page 25 of 67                                            Version date: 7/2/201 9   
 Attachment 1 : 
TEMPERATURE MONITORING LOG 
Clinical Site: ___________________________________  Site Number: _________________ PI [CONTACT_5627]: _____________________  
 Location of Refrigerator: ____________________________________________________________________________________  
Record daily refrigerator temperatures on the log provided.  Temperatures must be maintained between [ADDRESS_1137355] your CAP CRA for appropriate action and follow, if necessary . 
Month:  ________, 20_____  
 Day of Month  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 
Temp                                 
<-4ºC                                
-3ºC                                
-2ºC                                
-1ºC                                
0ºC                                
1ºC                                
2ºC                                
3ºC                                
4ºC                                
5ºC                                
6ºC                                
7ºC                                
8ºC                                
9ºC                                
10ºC                                 
11ºC                                 
12ºC                                 
13ºC                                 
>14ºC                                 
ESK981  2017 -065  
Karmanos Cancer Institute   
Esanik  Therapeutics Inc.                                                   Page 26 of 67                                            Version date: 7/2/201 9   
 Attachment 2: 
 
 
SITE INVESTIGATIONAL  DRUG SHIPPI[INVESTIGATOR_820631] T FORM  
Esanik  Therapeutics, Inc.  
Protocol GT -001 
 
Please Email to: BRIAN WOOD 
 
EMAIL: [EMAIL_15599]  
 
Protocol No./Investigational Agent:    
  ESK981 (CEP11981)  Site No./Investigator:  
 
Request Date:  Date Required On Site:  Number of Vials Requested:   
Ship To: (include attention personnel, full mailing address, phone and email for receiving party)  
 
 
 
 
 
 
 
Comments/Special Instructions:  
Institutional Requestor:  
Name  [CONTACT_820686]*: 
Name  [CONTACT_820687], original form must be filed in the Pharmacy Binder for this study . 
ESK981  2017 -065  
Karmanos Cancer Institute   
Esanik  Therapeutics Inc.                                                   Page 27 of 67                                            Version date: 7/2/201 9   
  
Pharmacokinetics  
Note: CEP -[ADDRESS_1137356] been  extensively 
studied in Sprague Dawley rats and cynomolgus monkeys after intravenous and oral  doses and 
preliminarily in Balb/c nude mice after oral doses. In order to facilita te comparisons  between 
studies and species, all doses are presented in this summary as milligrams of ESK981  free base per 
kilogram of body weight, regardless of the form administered, unless  specifically noted otherwise.  
The intravenous dose in rats was ad ministered in 3% dimethylsulfoxide, 30% Solutol®, and 67%  
phosphate -buffered saline at a volume of 1 mL/kg. In monkeys, the intravenous vehicle was  47.4% 
polyethylene glycol (PEG) 400, 31.1% water, 20.7% hydroxy -β-cyclodextrin (HPBCD),  and 0.8% 
Pluronic® F -68 at a volume of 0.5 mL/kg.  Pharmacokinetic parameters obtained after single 
intravenous (bolus) administration of ESK981  are summarized in  Table 4. 
Table 4. Pharmacokinetics After Single Intravenous Administration of ESK981 . 
 
In rats, the systemic clearance is low relative to the estimated total hepatic plasma flow; the  volume 
of distribution is approximately that of total body water. There are apparent sex -related  differences 
in the pharmacokinetics of ESK981  in rats, with lower clearance and longer  half-life in female rats 
than in male rats. The volume of distribution is numerically less in female  rats, but the significance 
of this difference i s doubtful.  
In monkeys, the half -life is similar to that in rats, but the systemic clearance is substantially  larger 
than that in rats, as is the volume of distribution. The difference in clearance is consistent  with the 
higher rate of metabolism of ESK981  in incubations with monkey liver microsomes  than with rat 
liver microsomes. The origin of the larger volume of distribution in monkeys is not  known.  
Pharmacokinetic parameters obtained after single, low -dose oral administration of ESK981  are 
summarized in  Table 4. 

ESK981  2017 -065  
Karmanos Cancer Institute   
Esanik  Therapeutics Inc.                                                   Page 28 of 67                                            Version date: 7/2/201 9   
 Table 5. Pharmacokinetics After Single Oral Administration of ESK981 . 
 
Dose administration in mice was as a suspension of the free base in 0.6% methylcellulose:Tween 80 
(99.5:0.5) at a volume of 25 mL/kg. In rats and monkeys, the dose was administered as a 
suspension of the tosylate salt in Ora -Plus oral suspending vehicle at  volumes of 2 and 5 mL/kg, 
respectively.  
Significant oral bioavailability was obtained in both rats and monkeys. The lack of an intravenous 
comparator dose in mice precluded calculation of the absolute bioavailability in that species, but 
the similarity in  systemic exposure in mice relative to rats would suggest that oral bioavailability is  
comparable.  
The effect of fed versus fasted state on the pharmacokinetics of ESK981  was assessed in a 
preliminary study in rats. C max and AUC 0-∞ were minimally affected by [CONTACT_820672]/fasted state of the 
animals, but the t max was shifted from 2.7 to 5.3 hours postdose when the animals had been fed 
before dosing.  
At higher oral doses of ESK981 , there was evidence of dose -dependent pharmacokinetics in all 
three species. In mice , single -dose systemic exposure increased in a slightly more than dose -
proportional manner between 1 and 10 mg/kg, but did not show consistent further increase at 20 
or 30 mg/kg. After 23 daily doses, the dose response and concentrations were similar to th ose after 
single doses at 1, 3, or 10 mg/kg, but were approximately two times higher in the 20 - and 30 -mg/kg 
groups on day 23 versus day 1 of dosing. Systemic exposure after multiple daily doses of 20 and 30 
mg/kg was dose -related, although not dose -propor tional, relative to that at 10 mg/kg.  
In male rats, C max was approximately dose proportional between 5 and 15 mg/kg, but was less than 
dose proportional between 15 and 40 mg/kg. The increase in AUC 0-∞ was greater than dose -
proportional between 5 and 15 mg/ kg, but was approximately dose proportional between 15 and 
40 mg/kg.  
In monkeys, increases in both C max and AUC 0-∞ were greater than dose proportional between 3 and 
13.5 mg/kg. Similar (i .e., greater -than -dose -proportional) increases in systemic exposure w ere also 
noted in a preliminary study that tested single oral doses as high as 100 mg/kg in monkeys.  
Due to changes in the form of ESK981  that was obtained from successive synthetic campaigns, a 
series of single -dose oral studies were conducted in rats and  monkeys to which different forms of 
the compound and/or different dosage regimens were administered. The outcome of those studies 
indicated that milled ESK981  tosylate, administered as a suspension in aqueous methylcellulose  
and provides systemic exposures that are in the targeted ranges in both species . It is that form with 

ESK981  2017 -065  
Karmanos Cancer Institute   
Esanik  Therapeutics Inc.                                                   Page 29 of 67                                            Version date: 7/2/201 9   
 which the bulk of the nonclinical toxicity testing was done and which will be the form of the 
compound used in early clinical testing.  
The tissue distribution of [14C] - ESK981  was studied in male albino (Sprague Dawley) and 
pi[INVESTIGATOR_49194] (Lister hooded) rats after single doses orally at 10 mg/kg and intravenously at 1 mg/kg, 
respectively, as the tosylate salt. Radioactivity was broadly distributed, with highest concentrations 
(exclu sive of the gastrointestinal tract) in the liver, kidney, and adrenal gland.  
Minimal radioactivity was detected in barriered tissues, i.e., brain and testis, but there was 
apparent association with melanin -containing structures such as uveal tract and pi[INVESTIGATOR_820632]. The bulk of the radioactivity was removed from the tissues during the [ADDRESS_1137357] periods in the albino and pi[INVESTIGATOR_246066], respectively.  
 ESK981  is extensively metabolized in vitro  by [CONTACT_820673]1 mice, male 
Sprague Dawley rats, male New Zealand rabbits, male beagle dogs, male cynomolgus monkeys, and 
humans. The relative order of loss of parent compound during 20 minutes of incubation was: 
monkeys > humans > mice ≈ dogs > rats ≈  rabbits.  
Incubations with individual recombinant human CYP enzymes suggested that three enzymes, ie, 
CYP1A2, CYP2C8, and CYP3A4, may play significant roles in the metabolic elimination of ESK981 . 
Other CYP enzymes that were also capable of metabolizing th e compound in vitro  are either 
minimally expressed in adult human liver (i .e., CYP1A1 and CYP3A7) or are polymorphic, being 
expressed in a minority of individuals (i .e., CYP3A5). The results of experiments assessing the effect 
of CYP -specific inhibitors on  loss of ESK981  during incubation with human liver microsomes also 
identified CYP3A enzymes as playing a key role in metabolic elimination of the compound.  
After oral administration of [14C] - ESK981 , radioactivity was predominantly recovered in the feces 
in both rats and monkeys, with less than 1% of the radiochemical dose recovered in urine of either 
species. Hence, metabolic profiling was conducted in rat bile, in which parent [14C] - ESK981  was 
the most prominent radioactive component, especially in the f emale rat.  
The most prominent metabolite in both sexes, but especially in the male, was a monohydroxylated 
derivative. Overall, the reactions previously observed in vitro , i.e., ring hydroxylation, N -
demethylation, and reduction (didehydrogenation) account ed for all of the ESK981 -derived 
compounds detected in vivo . 
The potential for ESK981  to affect the metabolic elimination of co -administered drugs was tested in 
vitro  through examination of its capacity for induction of CYP enzymes activities in primary hu man 
hepatocyte cultures and for inhibition of CYP activities in human hepatic microsomal preparations.  
The levels of mRNA for CYP1A1, CYP1A2, CYP2C9, and CYP3A4 were measured after incubation of 
ESK981  with hepatocytes for [ADDRESS_1137358].  
ESK981  did not i nhibit the activities of CYP2B6, CYP2C9, CYP2C19, CYP2D6, or CYP4A9/11. 
Marginal inhibition of CYP1A2 was observed, but with an estimated Ki that is higher than exposures 
expected clinically. CYP3A4/5 activity was inhibited with a Ki of 2.6 and 2.2 μM for the two 
reactions examined, i.e., testosterone 6β -hydroxylation and midazolam 1 ′-hydroxylation, 
respectively. Much of the inhibition was reversible and competitive in nature, with a metabolism -
dependent component, but at least some of the inhibition was ir reversible for both reactions tested.  
In addition to the pharmacokinetic and ADME studies, bioanalytical and pharmacokinetic support 
has been provided to the toxicokinetics portions of nonclinical safety studies in rats and monkeys.  
ESK981  2017 -065  
Karmanos Cancer Institute   
Esanik  Therapeutics Inc.                                                   Page 30 of 67                                            Version date: 7/2/[ADDRESS_1137359] nonclinical  safety study conducted to date in rats was a 4 -week oral toxicity study at 
daily doses of 0 (vehicle only), 5, 10, 20 (lowered to 15 on day 8), and 40 mg/kg.  ESK981  was 
administered as suspensions of its tosylate salt in Ora -Plus oral suspending vehicle.  Key 
toxicokinetic parameters from the study are tabulated in Table 6. 
Table 6. Toxicokinetics Results for the [ADDRESS_1137360]  study 
(study DS -2006 -020), daily doses of 0 (vehicle only), 5, 10, and 25 mg/kg were  administered as 
suspensions of the free base in Ora -Plus oral suspending vehicle. Due to a  subsequent change in the 
form of the com pound to its tosylate salt, a second 4 -week study  (study DS -2006 -042) was 
conducted testing daily doses of 0 (vehicle only) and 3 mg/kg. Key  toxicokinetic parameters from 
the study are tabulated in Table 7. 

ESK981  2017 -065  
Karmanos Cancer Institute   
Esanik  Therapeutics Inc.                                                   Page 31 of 67                                            Version date: 7/2/[ADDRESS_1137361](s) of the 
pharmacokinetics of the compound might be dose -dependent, especially at higher doses.  
Overall, the pharmacokinetic and ADME properties of ESK981  have been studied in vitro  usin g 
blood and tissue fractions from mice, rats, rabbits, dogs, monkeys, and humans and in vivo  in mice, 
rats, and monkeys. The estimated half -life in rats and monkeys after an intravenous dose is 
approximately 2 to 3 hours. Despi[INVESTIGATOR_820633] , ESK981  is generally well absorbed in 
mice, rats, and monkeys at dose levels associated with pharmacologic responses in preclinical 
disease models. At higher doses, evidence of dose -dependent pharmacokinetics has been obtained 
in all three species. After an oral or intravenous dose, [14C] -ESK981 -derived radioactivity is 
broadly distributed into tissues, generally at concentrations higher than those in blood. Only in 
barriered tissues, e.g., brain and testis, are concentrations lower than those in blood. Th e compound 
is extensively metabolized, but is also excreted in rats via the bile as the parent drug. Excretion is 
predominantly in the feces in both rats and monkeys.  
6.4 Dosage Selected, Preparation, and Schedule of Administration  
Treatment will be administered on an  outpatient  basis.  
6.4.1 Supply and packaging  
 ESK981  monotosylate is a fully synthetic drug substance containing a core  
indolocarbazolone ring system.  ESK981  monotosylate drug substance is a yellow to  
orange powder that has a molecular weight of 649.77 g/mol. The drug substance  contains 
73.5% theoretical weight percent of the active moiety ESK981  (free base).  
ESK981  drug product is an off -white to orange opaque, hard gelatin capsule  containing 40  
mg (free base equivalents) of ESK981  mono tosylate. The drug  product is packaged in a 

ESK981  2017 -065  
Karmanos Cancer Institute   
Esanik  Therapeutics Inc.                                                   Page 32 of 67                                            Version date: 7/2/201 9   
 high -density polyethylene (HDPE) bottle with a child resistant  closure and an induction -
sealed inner seal. The formulation also contains lactose  monohydrate.  
6.4.2 Storage and handling  
ESK981  capsules should be stored refrigerated at 2 C to 8C (36F to 46F). The stability of 
the drug substance and drug product continues to be monitored.  
6.5 Dose Modifications  
Patients with NCI -CTCAE Grade 3 or Grade 4 adverse events judged to be (at least po ssibly) 
related to ESK981 will have their ESK981 held until the adverse even t resolves to Grade [ADDRESS_1137362] management of adverse events should be  utilized.  Patients may then be 
restarted on ESK981 at a reduced dose of 120mg (3 capsules) daily for  [ADDRESS_1137363] possibly  related to ESK981 will be discontinued from the 
study.   If drug cannot be restarted within 3 weeks of bein g held, ESK981 should be 
discontinued.  Patients will also be discontinued for any of the following reasons:   
1. Worsening symptoms that can be attributed to prostate cancer  
2. Unacceptable adverse event(s) including development of a urinary outlet 
obstruction requiring urinary catheterization and/or surgical intervention,  
3. Intercurrent illness that prevents further participation,  
4. Patient refuses further treatment through the study and/or withdraws consent to 
participate , 
5. Patient is noncompliant with respect to taking drugs, keepi[INVESTIGATOR_55228], or 
having tests required for the evaluation of drug safety and efficacy, or  
6. General or specific changes in the patient's condition that render the patient 
unacceptable for further  treatment in this study in the judgment of the investigator.  
Under no circumstance will care of a withdrawn patient be adversely affected by a decision 
to withdraw or be withdrawn from the study  
6.6 Management of Expected  Toxicities  
Event Name  [CONTACT_635052]/Next Dose  
Grade 1  No change in dose  
Grade 2  No change in dose  
Grade 3 -4 Hold until < Grade 2.  Resume at one dose level lower, if 
indicated per Section 6.5. 
Recommended management:  antiemetics.  
 
Event Name  [CONTACT_820688]/Next Dose  
Grade 1  No change in dose  
Grade 2  No change in dose  
Grade 3 -4 Hold until < Grade 2.  Resume at one dose level lower, if 
indicated per Section 6.5. 
Recommended management:  antiemetics.  
 
ESK981  2017 -065  
Karmanos Cancer Institute   
Esanik  Therapeutics Inc.                                                   Page 33 of 67                                            Version date: 7/2/201 9   
 Event Name  [CONTACT_54977]/Next Dose  
Grade 1  No change in dose  
Grade 2  No change in dose  
Grade 3 -4 Hold until < Grade 2.  Resume at one dose level lower, if 
indicated per Section 6.5. 
Recommended management:  Loperamide anti -diarrheal therapy  
Dosage schedule:  [ADDRESS_1137364] onset, followed by 2 mg with each loose motion 
until diarrhea -free for 12 hours (maximum dosage:  16 mg/24 hours)  
Adjunct anti -diarrheal therapy is permitted and should be recorded when used.  
 
Event Name  [CONTACT_635054]/Next Dose  
Grade 1  No change in dose  
Grade 2  No change in dose  
Grade 3 -4 Hold until < Grade 2.  Resume at one dose level lower, if 
indicated per Section 6.5. 
Recommended management:  Use of growth factors is not recommended.  
Management of neutropenia should  be by [CONTACT_29874].  For grade 4 febrile 
neutropenia, discontinue treatment.  
 
Event Name  [CONTACT_820689]/Next Dose  
Grade 1  No change in dose  
Grade 2  No change in dose  
Grade 3 -4 Hold until < Grade 2.  Resume at one dose level lower, if 
indicated per Section 6.5. 
Recommended management:  Treat by [CONTACT_820674].  
 
Event Name  [CONTACT_635055]/Next Dose  
Grade 1  No change in dose  
Grade 2  No change in dose  
Grade 3 -4 Hold until < Grade 2.  Resume at one dose level lower, if 
indicated per Section 6.5. 
Recommended management:  Treat by [CONTACT_820674].  
 
Event Name  [CONTACT_820690]/Next Dose  
Grade 1  No change in dose  
Grade 2  No change in dose  
Grade 3 -4 Hold until < Grade 2.  Resume at one dose level lower, if 
indicated per Section 6.5 
. 
Recommended management:  Treat by [CONTACT_820675] -controlled blood pressure of < 150/90 mmHg.  
 
ESK981  2017 -065  
Karmanos Cancer Institute   
Esanik  Therapeutics Inc.                                                   Page 34 of 67                                            Version date: 7/2/201 9   
 Event Name  [CONTACT_820691]/Next Dose  
Grade 1  No change in dose  
Grade 2  No change in dose  
Grade 3 -4 Hold until < Grade 2.  Resume at one dose level lower, if 
indicated per Section 6.5. 
Recommended management:  Treat by [CONTACT_820676].  
 
Event Name  [CONTACT_820692]/Next Dose  
Grade 1  No change in dose  
Grade 2  No change in dose  
Grade 3 -4 Hold until < Grade 2.  Resume at one dose level lower, if 
indicated per Section 6.5. 
Recommended management: Identify appropriate arrhythmias such as atrial 
fibrillation, atrial flutter, atrioventricular blocks, and other conduction disorders. 
Treat appropriate medications or procedures as established by [CONTACT_9518].  
 
Event Name  [CONTACT_820693]/Next Dose  
Grade 1  No change in dose  
Grade 2  No change in dose  
Grade 3 -4 Hold until < Grade 2.  Resume at one dose level lower, if 
indicated per Section 6.5. 
Recommended management: Optimize supportive care.  
 
6.[ADDRESS_1137365] be documented on t he CRF . 
The principal investigator [INVESTIGATOR_820634] B (a listing of medications with  the poten tial for drug -drug interaction ).
6.7.[ADDRESS_1137366] to the restrictions due to  potential drug -drug interactions 
detailed in  Section 6. 7.3.   
6.7.2  Prohibited before enrollment and during administration of study treatment   
Concomitant systemic treatments for CRPC (other than a GnRH agonist/antagonist) are 
prohibited including: CYP -17 inhibitors (e.g. ketoconazole, abiraterone) , antiandrogens (e.g. 
bicalutamide, nilutamide), second generation antiandrogens (e.g. enzalutamide, ARN -509, 
Galeterone), immunotherapy (e.g. sipuleucel -T, ipi[INVESTIGATOR_125]),  and chemotherapy (e.g. 
docetaxel, cabazitaxel).  
6.7.[ADDRESS_1137367] the potential to increase plasma concentration of ESK981 . Inducers of 
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 35 of 67                                            Version date: 7/2/[ADDRESS_1137368] the potential to decrease plasma concentrations of 
ESK981 . Concomitant use of a medication known to be a potent inhibitor of CYP1A2, 
CYP2C8, or CYP3A4 (see Appendix B), or a potent inducer of CYP1A2, CYP2C8, or  CYP3A4 
(see Appendix B) should be avoided unless deemed to be medically necessary by [CONTACT_1275]. In addition, nonclinical studies have identified the potential for ESK981  to 
inhibit CYP3A4/5 (Ki 2.2μM).  ESK981  has the potential to increase plasma c oncentration of 
concomitant mediations that are CYP3A4/5 substrates. Caution should be used, or 
alternative treatments considered, if concomitant treatment with CYP3A4/[ADDRESS_1137369] a narrow therapeutic range is needed (see Appendix B).  
7. SAFETY  EVALUATION  
A safety review of the first six patients  who have been observed for [ADDRESS_1137370] been assessed for toxicity evaluation.  
7.1 Definitions  
7.1.1 Adverse Event (AE)   
Any untoward medical occurrence in a patient or clinical investigation subject administered a 
pharmaceutical  product and which does not necessarily have to have a causal relationship with 
this treatment  (ICH E2A) . An adverse event for the purposes of this protocol is the appearance of 
(or worsening of any pre -existing) undesirable sign(s), symptom(s), or medical condition(s) 
occurring after signing the informed consent even if the eve nt is not considered to be related to 
the study drug(s). An AE can therefo re be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of a 
medicinal product, whether or not related to the medicinal product.  
An abnormality ident ified during a medical  test (e.g.  laboratory parameter, vital sign, ECG data, 
physical exam) should be defined as an AE only if the abnormality meets one of the following 
criteria:  
 Requires active intervention  
 Requires interruption or discontinuation of study medication  
The abnormality or investigational value is clinically significant in the opi[INVESTIGATOR_1070] . An adverse event will be recorded and followed from treatment administration 
to [ADDRESS_1137371], the Investigator’s Brochure, the package in sert or is 
included in the informed consent document as a potential risk.  
7.1.[ADDRESS_1137372] information (e.g., Investigator's Broch ure for an unapproved investigational 
medicinal product)  (ICH E2A) . 
Contact [CONTACT_079] [INVESTIGATOR_820635].    
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 36 of 67                                            Version date: 7/2/201 9   
  
7.1.4  Adverse Drug Reaction (ADR)  
All noxious and unintended response s to a medicinal product related to any dose should be 
considered adverse drug reactions  (ICH E2A) .  
The phrase "response  to a medicinal product" means that a causal relationship between a 
medicinal product and an adverse event is at least a reasonable poss ibility, i.e., the 
relationship cannot be ruled out.  ‘‘Reasonable possibility’’ means there is evidence to 
suggest a causal relationship between the drug and the adverse event.  
7.1.5 Serious Adverse Event (SAE)  
An SAE/ADR as defined in the Code of  Federal Regulations ( 21 CFR § 312.32 ) is any event 
that:  
 results in death  
 is life -threatening  
 results in inpatient hospi[INVESTIGATOR_1081]  
 results in persistent or significant disability or incapacity  
 results in congeni tal anomaly or birth defect  
 is medically significant in the opi[INVESTIGATOR_820636]:  
 routine treatment or monitoring of the studied indication, not associated with any 
deterioration in condition, or for elective procedures  
 elective or pre -planned treatment for a pre -existing condition that is unrelated to 
the indication under study and did not worsen  since signing the informed consent  
 emergency outpatient treatment for an event not fulfi lling the serious criteria 
outlined above and not resulting in inpatient admission  
 respi[INVESTIGATOR_4594]  
7.1.6 Progression of malignancy  
Progression of a patient’s malignancy should not be considered an AE, unless in the 
investigator’s opi[INVESTIGATOR_1649], study treatment resu lted in an exacerbation of the patient’s 
condition. If disease progression results in death or hospi[INVESTIGATOR_820637] 
[ADDRESS_1137373] dose , progressive disease will be considered an SAE.  
7.1.7 Life-threatening   
An adverse event or sus pected adverse reaction is considered “ life-threatening  “if, in the 
view of either investigator or sponsor, its occurrence places the patient  or subject  at 
immediate risk of death. It does not include an adverse event or suspected adverse reaction 
that, had it occurred in a more severe form, might have caused death  (FDA 21 CFR § 
312.32 ). 
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 37 of 67                                            Version date: 7/2/201 9   
 7.1.8 Hospi[INVESTIGATOR_059] (or prolongation of hospi[INVESTIGATOR_5186] n) 
Hospi[INVESTIGATOR_820638] (even for less than 24 hours) 
resulting from a precipi[INVESTIGATOR_303338] g, treatment -emergent adverse event. For chronic or long -term 
patients, inpatient admission also includes transfer within the hospi[INVESTIGATOR_820639]. Hospi[INVESTIGATOR_820640] a nonworsening 
preexisting c ondition should not be considered AEs (e .g., admission for workup of a 
persistent pretreatment laboratory abnormality, yearly physical exam, protocol -specified 
admission, elective surgery). Preplanned treatments or surgical procedures should be noted 
in th e baseline documentation. Hospi[INVESTIGATOR_820641].  
Prolongation of hospi[INVESTIGATOR_820642].  
7.1.9 Persistent or Significant disability /incapacity  
Any AE that results in persistent or significant incapacity or substantial disruption of the 
patient’s ability to conduct normal life functions.  
7.1.[ADDRESS_1137374] be 
immediately reported to the sponsor -investigator . All pregnancies will be followed until 
resolution ( i.e., voluntary or spontaneous termination or birth) and assessed for congenital 
anomalies and birth defects.  
7.2 Recording and Grading  of Adverse Events  
7.2.1 Recording  
All observed or volunteered adverse events, regardless of treatment group, severity, 
suspected causal relationship, expectedness, or serio usness will be recorded  on the Medical 
History/Current Medical Conditions Electronic Case Report Form . 
The occurrence of adverse events should be sought by [CONTACT_105] -directive questioning of the 
patient at eac h visit during the study. Adverse events also may be detected when they are 
volunteered by [CONTACT_24479], 
laboratory test, or other assessments. As far as possible, each adverse event should be 
evaluat ed to determine:  
a. The severity grade (CTCAE grade 1 -4) 
b. Its relationship to each study drug  (suspected/not suspected)  
c. Its duration (start and end dates or if continuing at final exam)  
d. Action taken (no action taken; study drug  dosage adjusted/temporarily inte rrupted; 
study drug permanently discontinued due to this adverse event; concomitant 
medication t aken; non -drug therapy given; hospi[INVESTIGATOR_059]/prolonged hospi[INVESTIGATOR_059])  
Adverse events (but not serious adverse events) occurring before starting study treatme nt, 
but after signing the informed consent  form are recorded on the Medical History/Current 
Medical Conditions Electronic Case Report Form. Abnormal laboratory values or test results 
constitute adverse events only if they induce clinical signs or symptoms, are considered 
clinically significant or require therapy (e.g., any hematologic abnormality that requires 
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 38 of 67                                            Version date: 7/2/201 9   
 transfusion or cytokine treatment ), and should be recorded on the Adverse Events CRF 
under the signs, symptoms or diagnosis associated with them. In addition, isolated 
abnormal laboratory val ues that are considered clinically significant ( e.g., cause study 
discontinuation or constitutes in and of itself a Serious Adverse Event) should be recorded 
on the Adverse Events CRF. SAEs occurring after the start of treatment  are recorded on the 
Adverse  Event CRF.  
A clinically significant change in a physical examination finding or an abnormal test result  
should be recorded as an AE, if it:  
 is associ ated with accompanying symptoms , 
 requires additional diagnostic testing o r medical or surgical interventio n, 
 leads to a change in study dosing or  discontinuation from the study , 
 requires additional concomitant drug treatment or other therapy, or  
 is considered clinically significant by [CONTACT_093] .  
An abnormal test result that is subsequently determined t o be in error does not require 
recording as an adverse event, even if it originally met one or more of the above criteria.  
7.2.2 Grading severity  
Adverse events will be assessed according to the Common Toxicity Criteria for Adverse 
Events [CTCAE] version 4.03.  If CTCAE grading does not exist for an adverse event, the 
severity of mild, moderate, severe, and life -threatening, or Grades 1 - 4, will be used. CTCAE 
Grade 5 (death) will not be used  in this study; rather, this information will be collected in 
the End of Treatment or Survival Information CRF page. Adverse event monitoring should 
be continued for at least [ADDRESS_1137375] evaluate all AEs for 
possible causal relationship to  the investigational agent . Causality a ttribution will be 
decided using the criteria outlined in Table .  
Table 8. Relationship of Adverse Event to Study Drug  
Relationship  Description  
Unrelated  AE is clearly not related  
Unlikely  AE is doubtfully related  
Possible  AE may be related  
Probable  AE is likely related  
Definite  AE is clearly related  
7.3 Adverse Events  Reporting  
7.3.1 Regulatory and reporting requirements  
These will be followed per IND requirements (if applicable) as well as sponsor 
requirements  and WSU IRB requirements . 
7.3.2  WSU IRB Adverse Event Reporting Guidelines  
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 39 of 67                                            Version date: 7/2/201 9   
 Unexpected Problem – Risk to participant or others. A problem that is a) unforeseen, b) 
indicates that participants or others are at increased risk of harm, and c) is related or 
possibly related to the resea rch. The following are examples of unexpected problems:  
1. Adverse Event: Any harm experienced by a participant regardless of whether the event was 
internal (on -site) or external (off -site) and regardless of whether the event meets the FDA 
definition of “ser ious adverse event”, which in the opi[INVESTIGATOR_820643], related (definitely, probably, or more likely than not), and suggests 
that participants are at greater risk than was previously known or recognized.  
a. An adverse ev ent is “unexpected” when its specificity and severity are not accurately 
reflected in the informed consent document, the protocol or the investigator’s brochure.  
b. An adverse event is “related to the research procedures” if in the opi[INVESTIGATOR_820644] i nvestigator it was more likely than not to be caused by [CONTACT_485915], or if it is more likely than not that the event affects the rights and welfare of 
current participants.  
2. Any harm experienced by a participant or  others  as a result of involve ment in research 
activities (internal or external excluding  adverse events).  
3. Information that indicates a change to the risks or potential  benefits  of the research. For 
example:  
a. An interim analysis or safety monitoring report indicates that frequency or magnitude 
of harm or benefit may be different than initially presented to the IRB.  
b. A paper is published from another study that shows the risks or potential benefits to 
your research may be different than initially presented to the IRB.  
c. Study put on hold  by [CONTACT_978], FDA, or the Sponsor for reasons that may include safety, 
toxicity and/or efficacy.  
4. A change in FDA labeling  or withdrawal from marketing of a drug, device, or biologic used 
in a research protocol.  
5. Change to the protocol  taken without prior IRB review to eliminate an apparent 
immediate hazard to a research participant.  
6. Research conducted without prior WSU IRB approval.  
7. Event that requires prompt reporting to the sponsor.  
8. Unanticipated adverse device effect : Any serious  adverse effect on health or safety, or 
any life -threatening problem or death caused by, or associated with, a device if that effect, 
problem, or death was not previously identified in natured, severity, or degree of incidence 
in the investigational plan o r application (including a supplementary plan or application), or 
any other unanticipated serious problem associated with a device that relates to the rights, 
safety, or welfare of subjects.  
9. Sponsor -imposed suspension for risk.  
10. Complaint of a participant  when the complaint indicates unexpected risks or cannot be 
resolved by [CONTACT_5051].  
11. A breach of confidentiality.  
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 40 of 67                                            Version date: 7/2/201 9   
 12. Protocol violation/deviation  (meaning an accidental or unintentional change to the IRB -
approved protocol) that harmed participants or others, that indicates participants or others 
may have been placed at increased risk of harm, or rights of research participants were 
violated. For example:  
a. Failure to draw safety labs  
b. Request for continuation submitted late to the IRB three years in a r ow  
c. Wrong informed consent signed or failure to obtain informed consent  
13. Incarceration of a participant  in a protocol not approved to enroll prisoners.  
14. All deaths that have happened at WSU or one of its affiliates within [ADDRESS_1137376] report any of the above to the IRB as soon as possible, but in all cases 
within 5 working days.   
7.4     Serious Adverse Event Reporting   
Within 24 hours of awareness of a serious adverse event, whether or not related to the study 
drug, the investigator will complete and submit a Medwatch 3500a form,  containing all 
required information (reference CFR § 312.32 ). The investigator will submit a copy of this 
Medwatch 3500a form to the sponsor -investigator and Esanik  by [CONTACT_5640] e -mail or fax, within 
the same timeframe.  
The SAE documentation, including the Me dwatch 3500A form and available source records 
should be emailed or faxed to:  
Email: [EMAIL_15600]  
Fax: 610 -408 -0321  
The following minimum information is required:  
• study number  
• subject number, sex and age  
• the date of report  
• a description of the SAE (event, seriousness of the event)  
• causal relationship to the study drug . Follow -up information for the event should be sent within 
7 days as necessary. Copy of above should also be sent to coordinating sit e (PI - [CONTACT_820695] ).  
Sponsor -Investigator:  
Elisabeth I. Heath, MD FACP    Tel: 313 -576 -8717  
4100 John R      Fax: 313 -576 -8767  
Detroit, MI [ZIP_CODE]      Email: [EMAIL_13698]  
7.4.1   Safety Reporting Requirements for IND Holders   
In accordance with 21 CFR § 312.[ADDRESS_1137377] 
comply with following safety reporting requirements:  
Expedited IND Safety Reports:  
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 41 of 67                                            Version date: 7/2/201 9   
 7.4.2 Calendar -Day Telephone or Fax Report:    
The Sponsor -Investigator is required to notify the FDA of any fatal or life -threatening adverse event 
that is unexpected and assessed by [CONTACT_820677]981.  An 
unexpected adverse event is one that is not already described in the Investigator Brochure.  Such 
reports are to be telephoned or faxed to the FDA within [ADDRESS_1137378] learning of the 
event. Each telephone call or fax transmission (see fax number below) should be directed to the 
FDA new drug revi ew division in the Center for Drug Evaluation and Research or in the product 
review division for the Center for Biologics Evaluation and Research, whichever is responsible for 
the review of the IND.  
15 Calendar -Day Written Report:   
The Sponsor -Investigato r is also required to notify the FDA and all participating investigators, in a 
written IND Safety Report, of any serious, unexpected AE that is considered possibly related to the 
use of ESK981.  An unexpected adverse event is one that is not already descri bed in the Investigator 
Brochure.  
Written IND Safety Reports should include an Analysis of Similar Events in accordance with 
regulation 21 CFR § 312.32. All safety reports previously filed with the IND concerning similar 
events should be analyzed. The new report should contain comments on the significance of the new 
event in light of the previous, similar reports.   
Written IND safety reports with Analysis of Similar Events are to be submitted to the FDA, Esanik 
Drug Safety, and all participating investigat ors within [ADDRESS_1137379] learning of the event. 
The FDA prefers these reports on a MedWatch 3500a Form but alternative formats are acceptable 
(e.g. summary letter).  
FDA fax number for IND Safety Reports:  
1 (800) FDA -0178  
IND Annual Reports  
In accordance with the regulation 21 CFR § 312.32, the Sponsor -Investigator shall within [ADDRESS_1137380] submit a brief report of the progress of the 
investigation.  Please refer to Code of Federal Regulations, 21  CFR § 312.[ADDRESS_1137381] of ESK981  in pregnant and lac tating women is not known, and the exposure of a 
fetus or nursing infant is considered a potential risk. ESK981  can cause fetal harm when 
administered to a pregnant woman based on its mechanism of action. Subjects receiving 
ESK981  are advised to use two ac ceptable methods of birth control (one of which must 
include a condom as a barrier method of contraception) starting at the time of screening for 
an ESK981  study and continuing throughout the course of treatment and for at least three 
months after ESK981  is discontinued.  
If, during the conduct of the clinical trial, a male subject impregnates his partner, the subject 
should report the pregnancy to the investigator. The investigator should report the 
pregnancy to the sponsor as an SAE within [ADDRESS_1137382] menstruation, 
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 42 of 67                                            Version date: 7/2/201 9   
 estimated fertility date, pregnancy result and neonatal data etc., should be included in this 
information.  
The investigator should report t he outcome of the pregnancy (independent of outcome, e.g., 
full term delivery, pre -term delivery, spontaneous abortion, induced abortion, stillbirth, 
death of newborn, congenital anomaly [including anomaly in a miscarried fetus, etc .]) in 
accordance with the same reporting procedure as for SAEs. The date of outcome of the 
pregnancy, gestational age, date of birth and neonatal data etc., should be included in this 
information.  
8. CRITERIA FOR OUTCOME  ASSESSMENT/THERAPEUT IC RESPONSE  
8.1 Outcome Assessment  
All baseline evaluations will be performed as closely as possible to the beginning of 
treatment (< 4 weeks ). For subsequent evaluations, the method of assessment and  
technique s will be the same as those used at baseline . 
8.1.1 Measurement of clinical lesions  
Only superficial clinical lesions (e.g., skin nodules and palpable lymph nodes ) are 
considered  measurable. In the case of skin lesions, documentation by [CONTACT_6775], 
including a ruler to estimate the size of the lesion, is recommended.  
8.1.[ADDRESS_1137383] x -ray are acceptable as measurable lesions when they are clearly defined 
and su rrounded by [CONTACT_6776]; however, CT is preferable to x -ray. 
8.1.[ADDRESS_1137384], MRI, positron emission tomography (PET) , bone scan  
To assess the antitumor effect of a treatment, imaging -based evaluation is preferable to 
evaluation by [CONTACT_12148]. C T and MRI should be performed using contiguous slices 
of [ADDRESS_1137385] should be performed using a 5 -mm contiguous reconstruction 
algorithm (interval). If a 5 -mm contiguous reconstruction algorithm (interval) is not used, 
as a general rule, the lesion diameter should be no less than double the reconstruction 
algorithm (interval) and must be at least [ADDRESS_1137386]. (If available, spi[INVESTIGATOR_820645] .) A technetium -99m bone scan 
will be  performed at screening and at each tumor assessment during the study to evaluate 
bone metastasis. For adequate assessment of bone lesions, it is expected that the radiologist 
will adjust window leveling accordingly. PET scan will be used for bone scan if requested by 
[CONTACT_5936]. This applies to tumors of the chest, abdomen, pelvis  and bone . Head and neck 
tumors and those of the extremities typi[INVESTIGATOR_820646] .  
8.1.4 Ultrasound  
When the primary endpoint of the study is objective response, ultrasound should not be 
used to measure tumor lesions. Ultrasound may be appropriate, however, as a possible 
alternative to clinical measurements of superficial, palpable lymph nodes, subcutane ous 
lesions, or thyroid nodules, or to confirm the complete disappearance of superficial lesions 
(usually assessed by [CONTACT_12148]).  
8.1.5 Endoscopy/laparoscopy  
Using endoscopy of laparoscopy for objective tumor evaluation has not yet been fully 
validate d and should be restricted. These techniques may be useful, however, to confirm 
complete pathological response when biopsies are obtained.  
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 43 of 67                                            Version date: 7/2/[ADDRESS_1137387] normalize for a patient to be considered in complete clinical response.  
8.1.7 Cytology/histology  
In certain situations, cytology and histology can be used to differentiate response (e.g., 
residual lesions in tumor types, such as germ cell tumors, where known  residual benign 
tumors can remain). When the measurable tumor has met criteria for response or stable 
disease, c ytological confirmation of the neoplastic origin of any effusion that appears or 
worsens during treatment is mandatory to differentiate between  response , stable disease , 
and progressive disease.  
8.2 Therapeutic Response  
Response and progression will be e valuated in this study  using a combination of the revised  
Response Evaluation Criteria in Solid Tumors (RECIST  1.1) criteria15 and the guidelines for 
prostate cancer endpoints developed by [CONTACT_131806] 
(PCWG 3).3 
Trial objectives are defined based on controlling, relieving, or eliminating disease 
manifestations that are present when treatment is initiated, or preventing or delaying the 
development of disease manifestations that are expected to occur (or in some cases both). 
Identify whether control/rel ieve/eliminated or prevent/delay endpoints. Traditional 
measures of response reflect when a treatment is working and measures of progression 
indicate when a drug should be stopped. Because assessing response in bone (the most 
common site of prostate cancer  spread) is uncertain and the clinical significance of PSA 
changes in response to therapy is not a  reliable predictor of response, measures of response 
have been expanded in consortium trials to include measures of progression.  
Patients will need t o be reevaluated for response  every cycle (or more frequently if 
indicated), according to the guidelines below.
8.2.1 PSA  
In this study, PSA testing is being performed on days 8, 15, and 22  of Cycle 1 , Day  1 of Cycle 2 
and each subsequent cycle (every 4 weeks) with the threshold PSA level at 2.0 ng/mL.  To 
report PSA -based outcomes, PCWG 3 recommends that  the percent of change in PSA from 
baseline to 8 weeks (or earlier for those who discontinue therapy) and the maximum decline in 
PSA that occurs at any point after treatment be reported for each patient using a waterfall 
plot.3 Because the rate of rise has shown  prognostic significance, estimate a pretreatment PSA 
doubling time (PSA -DT) if at least [ADDRESS_1137388] one 
dimension (longest diameter to be recorded) as ≥ [ADDRESS_1137389] x -ray, as ≥ [ADDRESS_1137390] or 
MRI scan, or ≥ [ADDRESS_1137391] be 
recorded in millimeters. NOTE: tumor lesions that are situated in a previously irradiated area 
might or might not be considered measurable. If the investigator th inks it appropriate to 
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 44 of 67                                            Version date: 7/2/[ADDRESS_1137392] be ≥ [ADDRESS_1137393] or MRI scan (CT scan slice thickness recommended t be no 
greater than 5 mm). At baseline and in follow -up, only the short axis will be measured and 
followed.  
Non -measurable Disease  
All other lesions (or sites of disease), including small l esions (longest diameter < 10 mm or 
pathol ogical lymph nodes with ≥  10 to < 15 mm short axis) are considered non -measurable 
disease. Bone lesions, leptomeningeal disease, ascites, pleural/pericardial effusions, 
lymphangitis cutis/pneumonitis, inflammatory breast disease and abdominal masses (not 
followed by [CONTACT_462]) are considered as non -measurable. Non -measurable also includes 
lesions that are < 20mm buy chest x -ray. Cystic lesions that meet the criteria for 
radiographically defined simple cysts should n ot be considered as malignant lesions (neither 
measurable or non -measurable) sine they are, by [CONTACT_108], simple cysts. ‘Cystic lesions’ 
thought to represent cystic metastases can be considered as measurable lesions, if they meet 
the definition of measura bility described above. However, if non -cystic lesions are present in 
the same patient, these are preferred for selection as target lesions.  
Target Lesions  
All measurable lesions up to a maximum of 2  lesions per organ and 5 lesions in total, 
representative of all involved organs, should be identified as target lesions and recorded and 
measured at baseline. Target lesions should be selected on the basis of their size (lesions with the 
longest diameter) , be representative of all involved organs, but in addition should be those that 
lend themselves to reproducible repeated measurements. It may be the case that, on occasion, the 
largest lesion does not lend itself to reproducible measurement in which circu mstance the next 
largest lesion which can be measured reproducibly should be selected.  
A sum of the diameters (longest for non -nodal lesions, short axis for nodal lesions) for all target 
lesions will be calculated and reported as the baseline sum diameters . If lymph nodes are to be 
included in the sum, then only the short axis is added into the sum. The baseline sum of the 
diameters will be used as reference to further characterize any objective tumor regression in the 
measurable dimension of the disease.  
Non -target Lesions  
All other lesions (or sites of disease) including any measurable lesions over and above the [ADDRESS_1137394] slice thickness greater than 5 mm, the minimum 
size f or a measurable lesion should be twice the slice thickness. MRI is also acceptable in certain 
situations (e.g. for body scans).  
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 45 of 67                                            Version date: 7/2/[ADDRESS_1137395], spatial, and temporal 
resolution; however, there are many image acquisition variables involved in MRI which 
greatly impact image quality, lesion conspi[INVESTIGATOR_3934], and measurement. Furthermore, the 
availability of MRI is variable globally. As with CT, if an MRI is performed, the technical 
specifications of the scanning seque nces used should be optimized for the evaluation of the 
type and site of  disease. Furthermore, as with CT, the modality used at follow -up must be the 
same as was used at baseline and the lesions should be measured/assessed on the same pulse 
sequence. It is  beyond the scope of the RECIST guidelines to prescribe specific MRI pulse 
sequence parameters for all scanners, body parts, and diseases.  
Ideally, the same type of scanner should be used  and the image acquisition protocol should be 
followed as closely as possible to prior scans. Body scans should be performed with breath -hold 
scanning techniques, if possible.  
8.2.4      Methods for Evaluation of Bone  Disease  
Evaluation of Radionuclide Bone Scans : Bone disease will be evaluated using radionuclide bone 
scan.  NOTE:  Will follow PCWG3  
Interpretation of serial changes in a radionuclide bone scan is well recognized to be highly 
subjective. Thus, the primary outcome will be whether the bone sca n is stable or improved, vs. 
worse or progression. Changes in intensity will not be used as an outcome measure. The 2+2 rule 
will be applied for interpretation of bone scans:  
Stable or Improved : Include the appearance of at least [ADDRESS_1137396] -
treatment scan performed 6 or more weeks later or changes in intensity of a preexisting lesion 
will be considered stable disease unless associated with other signs of progression.  
Progression (Non -Response) : Must be documented as the appeara nce of at least two 
additional new lesions on the next scan after the first [ADDRESS_1137397] two 
additional new lesions are seen on the next (confirmatory) scan the date of progression is the 
date of the first post treatment san when t he first two new lesions were documented. An 
increase in the size or intensity of known skeletal lesions will not be considered progression . 
8.3 Response Criteria   
8.3.1. Evaluation of Target Lesions  
Complete Response  (CR)  
Disappearance of all target lesions. Any pathological lymph nodes (whether target or non -target) 
must have reduction in short axis to < 10  mm.  
Partial Response (PR)  
At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the 
baseline sum diameters . 
Progressive Disease (PD)  
At least a 20% increase in the sum of the diameters of target lesions, taking as reference the 
smallest sum on study (this includes the baseline sum if that is the smallest on study). In 
addition to the relative increase of 20%, the sum must also demonstra te an absolute increase of 
at least 5 mm.  NOTE:  The appearance of one or more new  lesions  is also considered 
progression  (see “Evaluation of New Lesions” below) . 
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 46 of 67                                            Version date: 7/2/201 9   
 Stable Disease (SD)  
Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as 
reference the smallest sum diameters while on study. (Note: a change of 20% or more that does 
not increase the sum of the diameters by 5 mm or more is coded as stable disease)  
To be assigned a status of stable disease, measurement s must have met the stable disease 
criteria at least once after study entry at a minimum interval of 8 weeks.  
In some circumstances, it may be difficult to distinguish residual disease from normal tissue. 
When the evaluation of complete response depends on  this determination, it is 
recommended that the residual lesion be investigated (e .g., fine needle aspi[INVESTIGATOR_5179]) 
before confirming the complete response status.  
Changes in nodal and visceral sites should be recorded and reported separately, and lymph  
nodes in the pelvis must measure at least [ADDRESS_1137398] diameter to be considered target 
lesions. C omplete elimination of disease at a particular site should be  recorded separately. 
Any favorable change should be confirmed using a second follow -up scan . 
8.3.2   Evaluation of Non -Target Lesions  
Complete Response  (CR)  
Disappearance of all non -target lesions. All lymph nodes must be non -pathological in size (< 
10 mm short axis).  
Non -CR/Non -PD 
Persistence of one or more non -target lesion(s) and/or the maintenance of tumor marker levels 
above the normal limits.  
Progressive Disease (PD)  
Appearance of one or more new lesions and/or unequivocal progression of existing non -target 
lesions (see “Evalu ation of New Lesions” below ). Unequivocal progression should not normally 
trump target lesion status. It must be representative of overall disease status change, not a single 
lesion increase.  
When the patient also has measurable disease, there must be an o verall level of substantial 
worsening in non -target disease such that, even in the presence of SD or PR in target disease, the 
overall tumor burden has increased sufficiently to merit discontinuation of therapy. A modest 
“increase” in the size of one or mo re non -target lesions is usually not sufficient to qualify for 
unequivocal progression status. The designation of overall progression solely on the  basis of 
change in non -target disease in the face of SD or PR of target disease will therefore be extremely 
rare.  
When the patient only has non -measurable disease, the increase in overall disease burden 
should be comparable in magnitude to the increase that would be required to declare PD for 
measurable disease: i.e., an increase in tumor burden from “trace” to “large”, an increase in 
nodal disease from “localized” to “widespread”, or an increase sufficient to require a change in 
therapy.  
Although a clear progression of “non -target” lesions only is exceptional, the opi[INVESTIGATOR_820647], and the progression status should be 
confirmed at a later time by [CONTACT_463] (or Principal Investigator).  
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 47 of 67                                            Version date: 7/2/201 9   
 8.3.3  Evaluation of New  Lesions  
The appearance of new lesions constitutes Progressive Disease (PD).  
A growing lymph node  that did not meet the criteria for reporting as a measurable or non -
measurable lymph node at baseline should only be reported as a new lesion (and therefore 
progressive disease) if it:  
• increases in size to ≥ 15 mm in the short axis,  or 
• there is new pathol ogical confirmation that it is  disease (regardless of  size).  
• new effusion or ascites that appears during treatment should only be reported as a new 
lesion (and therefore progressive disease) if it has cytological confirmation  of 
malignancy.  
8.3.4 PSA  Response  
As long as patient safety is the primary concern, in the absence of other indicators of disease 
progression, t herapy should not be discontinue d solely on the basis of a rise  in PSA  after 
week 8. 
PSA progression is defined as the date that a 25% o r greater incre ase and an absolute 
increase of 2.0 ng/mL or more from the nadir is documented and confirmed by a second 
value obtained 3 or more weeks later. Where no decline from baseline is documented, PSA 
progression is defined as a 25% increase from th e baseline value along with an increase in 
absolute value of 2 .0 ng/mL or more after [ADDRESS_1137399] response recorded from the start of treatment until 
either disease progression  or recurrence. The investigator’s determination of best overall 
response will be based  both on response criteria  and on confirmation criteria  (Table 9). To 
be assigned a status of partial response or complete response, changes in tumor 
measurements must be co nfirmed by [CONTACT_820678] 4-[ADDRESS_1137400] documented.   
Note : If unconfirmed progression noted at the first time point is not confirmed at a second time 
point, the next assessment time point after the first that meets the criteria for progression will 
be treated as time point 1.  
  
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 48 of 67                                            Version date: 7/2/[ADDRESS_1137401] tumor response as sessment due to rapid progression or toxicity will be 
considered nonresponders, will be included in the denominator for the response rate, and will be 
classified into one of the categories listed below:  
 death attributed to disease progression  
 early discont inuation attributed to disease progression  
 death attributed to drug toxicity  
 early discontinuation attributed to drug toxicity  
Note : If a subject  receives subsequent therapy before tumor progression is documented, the reason 
for changing therapy mu st be reported.  Reasons include clinical progression, drug toxicity, or 
secon dary therapy for maintaining  tumor response.
8.4 Confirmatory Measures/Duration of Response  (see Table 1 0 for specific PCWG3 
measures)  
8.4.[ADDRESS_1137402] date that  recurrent disease is objectively 
documented.  Duration of stable disease is measured from the start of treatment until the 
criteria for progression are met.  Table 9. Assessing Overall Response . 
Target Lesions  Nontarget Lesions  New Lesions  Overall Response  
CR CR No CR 
CR Incomplete response/SD  No PR 
PR Non -PD No PR 
SD Non -PD No SD 
PD Any  Yes or No  PD 
Any  PD Yes or No  PD 
Any  Any  Yes PD 
Abreviations: CR, complete response; PD, progressive disease; PR, partial response; SD,  stable disease.  
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 49 of 67                                            Version date: 7/2/201 9   
 8.4.3 Progression -free survival  
Progression -free survival (PFS) is a composite endpoint defined  as the time from study 
entry or random assignment to disease progres sion in bone or soft -tissue, symptoms, or 
death. Use an interval -censored approach in which all assessments of the composite PFS 
endpoint (i .e., PSA, bone, CT scans,  and symptom assessments) are performed at the same 
time points. All assessments of disease  should be collected at the same time interval ( e.g., 
bone scan, CT scan, and PSA at 12 -week intervals ). In addition to PSA, confirm  post -
treatment changes in measurable target lesions, radio nuclide bone scans, and symptoms.  
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 50 of 67                                            Version date: 7/2/201 9   
 Table 10. Prostate Cancer Clinical Trials Working Group 3 (PCWG3) Outcome Measures . 
Variable  Control/Relieve/Eliminate Endpoints  Prevent/Delay Endpoints  
PSA  Record the percent change from baseline 
(rise or fall) at 8 weeks and, separately, 
the maximal change (rise or fall) at any 
time using a waterfall plot  Decline from baseline: record time from 
start of therapy to first PSA increase that is 
~25% and ~2.0 ng/mL above the nadir, and 
which is confirmed by a second value 3 or 
more weeks later (i.e., a confirmed rising 
trend) †  
Recording the duration of PSA decline of 
little value  
No decline from baseline: PSA progression 
~25% and ~2.0 ng/mL after [ADDRESS_1137403] with caveats:  
Only report changes in lymph nodes that 
were ~[ADDRESS_1137404] scheduled reassessment:  
No new lesions: continue therapy  
New lesions: perform a confirmatory scan 
6 or more weeks later  
Confirmatory scan:  
No new lesions: continue therapy  
Additional new lesions: progression  
Subsequent scheduled reassessments:  
No new lesions: continue  
New lesions: progression  The appearance of ~[ADDRESS_1137405] scan that shows the change  
Symptoms  Consider independently of other outcome measures  
Document pain and analgesia at entry with a lead -in period and measure repeatedly at 3 - 
to 4-week intervals  
Perform serial assessments of global changes in HRQOL, urinary or bowel compromise, 
pain management, additional anticancer therapy  
Ignore early changes (~12 weeks) in pain or HRQOL in absence of compelling evidence of 
disease progression  
Confirm response or progression of pain or HRQOL endpoints ~3 weeks later  
Abbreviations: PSA, prostate -specific antigen; HRQOL, health -related quality of life.  
†Particularly important when anticipated effect on PSA is delayed or for biologic therapi[INVESTIGATOR_014].  
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 51 of 67                                            Version date: 7/2/201 9   
 9.      CORRELATIVES  
The correlative assessments in this section are proposed as tertiary or exploratory 
objectives of the study. If exceptional responders/non -responder s are observed, the 
comprehensive sequencing based profiling of tumors is expected to d elineate putative 
molecular biomarkers, and refine the understanding of ESK981 ’s mechanism of action.  
9.1  The Association of Somatic and Germline Mutations with Exceptional  Response/Resistance 
to ESK981  
 
In addition to the prevalent TP53 mutations, AR amplifications, and ETS -fusions, mutations 
in the PTEN -PI3K -AKT pathway as well as germline and somatic events in the DNA repair 
pathway are frequently observed in mCRPC tumors. We propose integrative genomic  
sequencing to comprehensively profile the spectrum of genetic aberrations. The specific 
endpoints will be: activation through a hotspot mutation or amplification (gain -of-function), 
and inactivation through two -hit missense/nonsense mutation or deletion ( loss-of-
function) for genes from select pathways recurrently altered in mCRPC. Somatic and 
germline mutations will be identified through DNA sequencing of tumor and matched 
patient normal tissue utilizing the Oncoseq1700 platform . NGS -based analyses of cop y-
number alterations (CNA) and loss -of-heterozygosity (LOH) will be employed to probe for 
focal amplifications (e.g. AR, CCND1, PIK3CB) and deletions (e.g. PTEN, RB1).  
9.2  The Association of ETS / Kinase Gene Fusions with Exceptional Response/Resistance t o 
ESK981  
Capture RNA sequencing will be used to detect f urther genetic events, such as activating and 
inactivating genes fusions. It is expected that this will identify activating ETS fusions (ERG, 
ETV1, ET4, ETV5), driver kinase fusions (BRAF, RAF1, FGFR2 , FGFR3), as well as additional 
inactivating events in tumor suppressors (e.g. PTEN, TP53, RB1, BRCA1/2, ATM). To 
increase statistical power, mutations will be evaluated for association with clinical 
outcomes, both independently and grouped by [CONTACT_820679]: PTEN -PI3K -AKT, 
homologous recombination (e.g. BRCA1, BRCA2, PALB2), cell -cycle checkpoints (e.g. RB1, 
CCND1).  
9.3  The association of AR signaling with Exceptional Response to ESK981  
Further more , since modulation of androgen receptor (AR) signaling  through tyrosine 
kinases is observed as a mechanism of resistance to androgen deprivation therapy and 
androgen -independence, we hypothesize that the loss of dependence on AR signaling will 
be an additional independent predictor of response and outcomes. T he trial is designed to 
enrich for AR -independent patients in the Enza/Abi -refractory cohort who  will allow us to 
evaluate our hypotheses. Aggregate scores of AR -dependence and AR -independence will be 
derived from the expression levels of canonical AR targ ets and trans -differentiation 
markers.  
9.4  Metastatic Kinome Activity Profiles as Predictive Biomarkers for Response to ESK981  
Since the mechanism of ESK981 is based on the multiplex inhibition of a set of protein 
kinases we hypothesize that a tumor’s dep endence on kinase signaling pathways (kinome 
activity profile) will correlate with sensitivity to multiplex kinase inhibition by [CONTACT_820661]981. 
Similarly, kinome activity profiles will be quantified through the expression levels of 
individual tyrosine and serine/ threonine kinases targeted by [CONTACT_820661]981 and, by [CONTACT_820680], the activity of their downstream signaling pathways. The activity of 
each targeted kinase will be correlated with the clinical endpoints independently, and in 
conjunction wit h the tumor’s AR status and other genetic alterations.  
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 52 of 67                                            Version date: 7/2/201 9   
 9.5  Evaluation of Circulating and Disseminated Tumor Cells as Pharmacodynamic Biomarkers 
of ESK981 response.   
The burden of circulating (CTC) and disseminated tumor cells (DTC) has been associated 
with survival in a number of solid tumors. Further, a decrease in the number of CT C is a 
reliable indicator of response for a number of oncological therapi[INVESTIGATOR_014]. Therefore, we 
hypothesize that ESK981 treatment will reduce the burden of CTCs in the blood and DTCs 
obtained from the bone marrow. Blood samples will be collected at intervals of 4 weeks for 
the total duration of treatment ( from screening to end of treatment ). Circulating Tumor 
Cells (CTC) will be enriched from 7.5ml of whole blood using the AdnaTest 
ProstateCancerSelect assay. The expression of marker genes associated with androgen 
signaling, cell proliferation, kinome activity, autophagy, will be assessed pre -amplified 
cDNA (AdnaTest ProstateCancerDetect) using qPCR. In addition,  blood sample s will be 
processed using RareCtye platform for further characterizing CTC s in single cell level. 
Similarly, to detect DTCs bone marrow aspi[INVESTIGATOR_820648]. DTCs will be enriched by 
[CONTACT_117377] (lymphocyte markers) and positive (epi[INVESTIGATOR_255951]) selection using flow 
cytometry. The enriched DTCs will be profiled for single -cell gene expression using the 10X 
genomics sequencing platform (The Chromium System). Specifically, we will evaluate 
whether clinical response is associated with: (i) t he pre -treatment CTCs/DTC burden, (ii) a 
reduction in CTCs/DTCs during response, (iii) changes CTC/DTC expression profiles. Forty 
(40) ml of whole blood will be collected at each respective time -point, please see lab manual 
for collection and processing gu idelines.  
9.[ADDRESS_1137406] responses to ESK981 treatment.  
ESK981 treatment results in a striking and conserved phenotype (autophagy) in preclinical 
in vitro  and in vivo  models. However, the drug can in principle target other kinases 
expressed in normal cells from the tumor microenvironment  for example.  To differentiate 
between the direct and indirect effects of ESK981 , we will collect tumor biopsies from 
baseline  and 8 weeks of treatment for histopathological eval uation. We will perform 
immunohistochemistry (IHC) for the following protein markers: Ki67 (cell proliferation); 
AR (androgen receptor); CD31, NG2 and desmin (angiogenesis); PDGFR1/2, VEGFR1/2, 
Tie2, c -Kit, FGFR  (tyrosine kinase receptor); LC3 (autophagy).  We will evaluate whether 
treatment response is associated with a phenotypic change in the tumor histology 
(vacuolization), microenvironment (vascularization, immune infiltration), and the tumor's’ 
molecular characteristics (AR status, kinome profile).  
10. DATA REPORTING AND REGULATORY REQUIREME NTS  
10.1 Data Collection and Management  
Data collected during this study will be e ntered into a secure database . 
10.1.1 Electronic Case Report Forms  (eCRFs)  
Data will be collected and maintained on study specific electronic case report forms in the 
Oncore Research Enterprise system at Karmanos Cancer Institute. Training and support will 
be provided for all staff entering data upon local regulatory approval. Data entry must occur 
within 2 weeks of visits along with submission of applicable source documentation. KCI is 
responsible for ensuring eCRF’s are complete d accurately and submitted in a timely 
manner.  
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 53 of 67                                            Version date: 7/2/[ADDRESS_1137407]’s  research record.  
10.1.[ADDRESS_1137408] of the 
study to be fully documented and the study data to be subsequently verified. After study 
closure, the investigator will maintain all source documents  and study -relate d documents . 
Records are to be retained and securely stored until the later of: (a) two (2) years following 
the date a New Drug Application is approved for the Study Drug that is the subject of the 
Clinical Trial; or (b) two (2) years after the Investigati onal New Drug Application for such 
Study Drug is terminated or withdrawn, or such longer period of time as may be required 
by [CONTACT_294612], applicable laws, rules or regulations.  
10.1.4  Data Submission Timelines  
All d ata should be transmitted within 14 days of visit except for SAE submission (see  section 7.4 ).  
10.1.[ADDRESS_1137409]  
Any change or  addition (excluding administrative) to this protocol requires a written 
protocol amendment that must be reviewed and approved. Amendments significantly 
affecting the safety of subjects, the scope of the investigation or the scientific quality of the 
study  require additional approval by [CONTACT_1201]. A copy of the written approval of the IRB must 
be provided. Examples of amendments requiring such approval are:  
1. increases in drug dose or duration of exposure of subjects,  
2. significant changes in the study design ( e.g. addition or deletion of a control group),  
3. increases in the number of invasive procedures,  
4. addition or deletions of a test procedure required for monitoring of safety.  
These requirements for approval should in no way prevent any immediate action fro m 
being taken by [CONTACT_820681]. If an immediate change to the protocol is felt to be necessary by [CONTACT_820682] [INVESTIGATOR_820649]. Amendments affecting only administrative aspects of 
the study do not require formal protocol amendments or IRB approval but the IRB must be 
kept informed of such administrative changes. Examples  of administrative changes not 
requiring formal protocol amendments and IRB approval include:  
1. changes in the staff used to monitor trials  
2. minor changes in the packaging or labeling of study drug  
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 54 of 67                                            Version date: 7/2/[ADDRESS_1137410] of the protocol.   
10.2.2 During  these meetings the inve stigators will discuss matters related to:  
 Safety of protocol participants (Adverse Event reporting)  
 Validity and integrity of the data  
 Enrollment rate relative to expectation of tar get accrual, characteristics of participants  
 Retention of participants, adherence to the protocol (potential or real protocol 
violations)  
 Data completeness on case report forms and complete source documentation  
10.2.3 Completed Data and Safety Monitoring Reports of these regular investigator meeting s will 
be kept on file in the office of the Clinical Trials Core  (see form in Appendix F). The data 
manager assigned to the clinical trial will be responsible for completing the report form. 
The completed reports will be reviewed and signed off by [CONTACT_079] (PI) or 
by [CONTACT_454121] -PI’s in the absence of the PI. The signed off forms will then be forwarded to 
the Director, Clinical Trials Core for review of completeness and processing with the Data 
and Safety Monitoring Committee.  
10.2.[ADDRESS_1137411] been filed.  
11. STATISTIC AL CONSIDERATIONS  
11.1 Objectives  
The primary objectives  of this study are:  
1) To determine the PSA ≥ 50% response rate (PSA5 0) from baseline using the PCWG3 criteria 
to ESK981  as a single agent in men wi th mCRPC who have progressed on e nzalutamide (an ora l 
andro gen-receptor inhibitor) and/or a biraterone acetate (an androgen synthesis inhibitor).  
2) To a ssess the safety and tolerability of ESK981  as a single agent.  
The secondary  objectives of this study are:  
1) To determine the time to PSA response (TTPR) to ESK98 1 in patients with mCRPC  
2) To determine the duration of PSA response (PRD) to ESK981 in patients with mCRPC  
3) To determine PSA progression rates as defined by [CONTACT_338532]3 criteria.  
4) To determine PSA progression free survival ( PPFS)  as defined by [CONTACT_338532]3 criteria . 
The correlative/exploratory/tertiary objectives  of this study are:  to assess exploratory 
biomarkers from blood and tumor biopsies.  Examples of these may include, but are not limited to: 
whole exome sequencing, capture wh ole transcriptome analysis, AR and ARv7 analysis, ki -67, 
apoptosis, etc.  
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 55 of 67                                            Version date: 7/2/[ADDRESS_1137412] primary endpoint (PSA50) is a PSA decline of ≥ 50% from baseline (PSA50), using 
the PCWG3 criteria.   Refer to Section  8.2.1.  
The second primary endpoint(s) (toxicities) is (are) defined in Section 7.   Adverse events of 
all grades will be captured by [CONTACT_29630] - Common Terminology Criteria 
for Adverse Events, version 4.03 (NCI -CTCAE v4.03) and GCP standards.  
11.2.2  The secondary endpoints are defined as follows : 
Time to PSA response  (TTPR) is defined as the time from treatment start until the first 
documented occurrence  of PSA50.    PSA50 is defined in Section  1.3. 
Duration of PSA response  (PRD) is defined as  the time from start of PSA50 until PSA 
progression (defined in Section 8.3.2).  
PSA progression free survival ( PPFS) is defined in Section 8.3.2  except that it will be based 
on PSA assessments only.    PSA progression rates will be estimated from the PSA -only PFS 
distribution.  
11.2.3  The correlative/exploratory/tertiary endpoints (and the methods of their determination) 
are described in Section  9.         
11.3 Design  
11.3.1  We will utilize a single  group single -stage Phase II design for the study. Patients will receive 
160mg (4 capsules) of ESK981 dosed once daily for five consecutive days followed by a two 
consecutive day treatment break, for a cycle of 28 days. After 8 weeks (2 cycles) of ESK 981, 
patients  will be evaluated for their rate of PSA de cline of ≥ 50% from baseline (PSA50), 
using the PCWG3 criteria. Extrapolating from the data summarized on PSA50 response at 
any time by [CONTACT_515754] ,16 we hypothesize that the 8 -week PSA50 rate in patients similar to 
patients eligible for this protocol is approximately 20% . We also hypothesize that the 8 -
week PSA50 rate for ESK981 treated patients will be approximately 30% .   
11.3.2  We seek preliminary evidence that the true 8 -week PSA50 rate for patients on ESK981 
exceeds the hypothesized reference value of 20%. Having a directional hypothesis, the 
PSA50 rate will be estimated  with a 1 -sided Wilson type 90% lower confidence interval 
(CI).  With precision defined as a CI half -width (distance from the PSA50 estimate to the 
lower 90% confidence limit (CL)) of 0.1 00, a sample size of N= 27 patients and a sample 
estimate of PSA50 = 30% would have a lower CL = 0.201. This would indicate that the 
true 8 -week PSA50 rate was > 20%, with 90% confidence.  
11.3.3  The required sample size of N= 27 was determined from the “Confidence Intervals for 
One Proportion” program  within the PASS 15 software .17   
11.3.4   Sample size adjustment for non -compliance will be made as follows.  A major goal of this 
study is to evaluate the effic acy ( in addition to the effectiveness) of  ESK981  upon the 
PSA50 rate, safety, and tolerability . For each individual patient, w e will allow for a n 
ESK981 treatment non-compliance of up to 25%  (i.e., up to 25% of pi[INVESTIGATOR_820650]) .    
Our initial analytic focus will be on the patients who are eligible (per Section 3), and 
evaluable ( i.e., were on treatment for at leas t Cycle 1 [28 days]), and compliant ( took at 
least 75% of the intended ESK981 pi[INVESTIGATOR_820651] 1 ).    
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 56 of 67                                            Version date: 7/2/201 9   
     The patients meeting all 3 such requirements will be considered the eligible, evaluable, 
and compliant ( “EEC ”) subset.  We anticipate that up to  15% of the enrolled patients  will 
not become EEC for one reason or another.     
    To obtain the requisite 27 ESK981 compliant  patients  (i.e., completely  EEC) allowing for 
an overall attrition rate (“a”) of up to  15% of patients , we will need to enroll up to  N’ = [ N 
/ (1 – a)] = [27 / (1 – 0.15)] = 27 / 0. 85 = 32 patients .   
 The consequence of non -compliance (i.e, not being completely EEC) is that such patients 
would still be utilized in analyses of the effectiveness of ESK981. For example, that would 
focus o n the patients who were “EE” but not compliant. Another effectiveness analysis 
would focus on the patients who were eligible, but neither evaluable or compliant.   All of 
these analyses of non -EEC patients would be viewed as sensitivity analyses of  the effi cacy 
analysis of only the EEC patients . These supplemental analyses would provide a more 
complete assessment of the feasibility and efficacy combined  of the oral ESK981 
treatment in this study population.  
11.4 Analysis  
11.4.1   For the Primary Objectives , all analyses point and (1 -sided Wilson type 90% lower) CI 
estimates of the primary endpoint (PSA50) will be calculated.  
Adverse events will be tabulated by [CONTACT_820683] – Common Terminology Criter ia for Adverse Events (CTCAE) version 4.03.    
Other statistics will include point and (2 -sided) CI estimates of overall toxicity and of 
specific types of toxicity.  
11.4.[ADDRESS_1137413] deviation (SD), 
interquartile range (IQR), minimum, and maximum . 
11.4.3  For Secondary Objectives 2 and 3, the censored distributions of duration of response (RD) 
and PSA pr ogression free survival (PFS) will be summarized with the Kaplan -Meier (K -M) 
survivorship estimate . A graph of the K -M curve for PRD and for PPFS will be generated 
along with the Hall -Wellner 90% confidence band, and a display of the number of patients 
at risk at several time points, below the X -axis. Summary statistics ( 6-month rate, 12-month 
rate, median, etc.) will be calculated from the K -M life table, each one with its respective 
80% confidence interval (CI).   
11.4.4  For the Correl ative (Exploratory) Objectives,  frequency distributions of all categorical 
variables (grade of specific types of toxicity, and categorical biomarkers or other 
correlatives) will be generated.  Serial PSA levels will be displayed using spaghetti plots, and 
changes in PSA using  waterfall plots.  
Descriptive statistics will be used to summarize all continuous correlatives (e.g., PSA, 
continuous biomarkers and other correlatives), and changes in them pre/post ESK981 
treatment. Gene expression levels will be log 2 transformed prior to descriptive analysis.  
Multiple boxplots and scatterplots will be used to display summary statistics of 
biomarkers/correlatives and interrelationships between continuous correlatives, 
respectively.  
Details of the planned determination  of bioinformatics correlatives are  given in Section 9.    
Response (whether PSA50 or overall), a categorical clinical outcome, will be statistically 
modeled as a function of each correlative using exact logistic regression. TTPR , a continuous 
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 57 of 67                                            Version date: 7/2/201 9   
 uncensored cl inical outcome (limited to only the PSA50 responders) , will be statistically 
modeled as a function of each correlative  using linear regression.  
Time to event clinical outcomes ( PRD and PPFS) will be statistically modeled as a function 
of each correlative  using Cox proportional hazards regression. Examples of categorical 
corr elatives include:  gene mutation status (Sec. 9.1 and 9.2) ; AR  dependence (Sec. 9.3) ; and  
vacuolization status or vascularization  status ( Sec. 9.6) . Examples of continuous correlatives 
include:  kinase expression levels (Sec. 9.4) ; CTC  and DTC counts (Sec. 9.5 ); and levels of 
Ki67, AR, and LC3 (Sec. 9.6).  
11.5 Expected Accrual Rate, Accrual Duration, and Total Study Duration   
11.5.1 This will be a clinical trial  invo lving Karmanos Cancer  Institute (KCI ) only. We expect to 
accrue  10-12 patients/year .   
11.5.2  At that rate, we can accrue  32 patients (to obtain 27 EEC patients ) in  32-38 months . 
Allowing an additional 4 months to finish determin ing all bio markers and correlatives in all 
patients yields an estimated total study duration of  36-42 months.   
12. REGULATORY AND PROTECTION OF HUMAN SUBJECTS  
12.1 Roles and Responsibilities  
12.1.1 Sponsor Investigator  
The Sponsor Investigator  is responsible for performing the following tasks:  
 Responsibility for the overall conduct of the study and  for monit oring the progress 
of the study  
 Reviewing and ensuring reporting of Serious Adverse Events (SAEs)  
 Reviewing data  
12.2 Ethical Considerations  
This study will be conducted in compliance with th e protocol, GCP guidelines established by 
[CONTACT_5787], and the ethical standards set forth in the 
Declaration of  Helsinki 2004 (available at: www.laakaril iitto.fi/e/ethics/helsinki.html ). 
12.3 Written Informed Consent  
Befo re obtaining consent, members of the study team will review the rationale for the 
treatment program with the patient. The discussion will review the alternatives available 
(including hormonal therapy, chemotherapy, or supportive care as appropriate), the 
potential benefits of this program, the risks and the probability of their occurrence, and the 
proce dures to minimize these risks. Should an adverse event occur, t he provisions available 
to ensure medical intervention will also be reviewed. Why the risks ar e reasonable in 
relation to the anticipated benefits, incentives, or costs that will or may be incurred as a 
result of participating in the study, as well as the efforts to maintain confidentiality, will also 
be discussed  with the patient . 
Patients will be  required to sign and date a n informed consent form that meets the 
requirements of the Code of Federal Regulations (Federal Register Vol. 46, No. 17, January 
27, 198 1, part 50) and the IRB. The medical record will include a statement that written 
informed consent was obtained (and document  the date that it was obtained) before the 
patient is enrolled in the study. The original signed document will become part of the 
patient’ s medical record , a copy will be forwarded to the lead site/sponsor pursuant to 
spon sor registration and to the PCCTC and a copy will be sent home with each patient.  
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 58 of 67                                            Version date: 7/2/201 9   
 The consent form will include the following:  
 the nature and objectives, potential toxicities, and benefits of the intended study  
 the length of therapy and likely follow -up re quired  
 alternatives to the proposed therapy (including  available standard and 
investigational therapi[INVESTIGATOR_014])  
 the name [CONTACT_6823](s) responsible for the protocol  
 the right of the patient to accept or refuse treatment and to withdraw from 
participation in this study  
 Text regarding the consortium and the coordinating center should be added to all 
institutional informed consent documents and sections in the research 
authorization/HIPAA forms (e .g., “Prostate Cancer Clinical Trial Consortium”)  
12.4 Protecti on of Privacy  
Patients will be informed of the extent to which their confidential health information 
generated from this study may be used for research purposes. After  this discussion, they 
will be asked to sign a Notice of Privacy Practice research author ization/HIPAA form. The 
original signed documents will become part of the patient’s medical records, and each 
patient will receive a copy of the signed documents. The use and disclosure of protected 
health information will be limited to the individuals des cribed in the research authorization 
form. The research authorization form must be completed by [CONTACT_458] [INVESTIGATOR_820652].  
12.5 Terminating or Modifying the Study  
Adverse event and laboratory data from this trial wi ll be assessed b y the lead site or the 
sponsor’s medical monitor on an ongoing basis. SAE s will be reviewed as they are reported 
to the lead site/ sponsor,  and the medical monitor will make an assessment regarding the 
safety of continuing or modifying the study. This asses sment will be shared with the 
investigators either in writing or as part of a teleconference. Should the assessment of 
either the lead site/sponsor or the principal investigator [INVESTIGATOR_820653];  the study will be closed to further ac crua l. Patients who are receiving  an 
investigational agent  will be assessed individually by [CONTACT_820684]’  best interest  to continue, which mi ght be the case for a patient  that is responding 
to the intervention . Follow -up safety assessments will be performed for all patients who are 
terminated from the study prematurely.  
  
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 59 of 67                                            Version date: 7/2/201 9   
 13.0 REFERENCES  
1. Yang ZJ, Chee CE, Huang S, Sinicrope FA. The role of autophagy in cancer: therapeutic 
implications. Mol Cancer Ther  2011; 10(9): 1533 -41. 
2. American Cancer Society. Cancer Facts & Figures 2016. Atlanta, GA; 2016.  
3. Scher HI, Morris MJ, Stadler WM, et al. Trial Design and Objectives for Castration -Resistant 
Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials 
Working Group 3. J Clin Oncol  2016.  
4. Ferraldeschi R, Pezaro C, Karavasilis V, de Bono J. Abiraterone and novel antiandrogens: 
overcoming castration resistance in prostate cancer. Annu Rev Med  2013; 64: 1-13. 
5. Ryan CJ, Sm ith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without 
previous chemotherapy. N Engl J Med  2013; 368 (2): 138 -48. 
6. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after 
chemotherapy. N Engl J Med  2012; 367 (13): 1187 -97. 
7. Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate 
cancer: results of a Phase II randomized discontinuation trial. J Clin Oncol  2013; 31(4): 412 -
9. 
8. Smith M, De Bono J, Sternberg C, et a l. Phase III Study of Cabozantinib in Previously Treated 
Metastatic Castration -Resistant Prostate Cancer: COMET -1. J Clin Oncol  2016.  
9. Nelson PS. Targeting the androgen receptor in prostate cancer --a resilient foe. N Engl J Med  
2014; 371 (11): [ADDRESS_1137414], et al. The mutational landscape of lethal castration -resistant 
prostate cancer. Nature  2012; 487 (7406): 239 -43. 
11. Qiao Y, Feng FY, Wang Y, et al. Mechanistic Support for Combined MET and AR Blockade in 
Castration -Resistant  Prostate Cancer. Neoplasia  2016; 18(1): 1 -9. 
12. Hudkins RL, Becknell NC, Zulli AL, et al. Synthesis and biological profile of the pan -vascular 
endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epi[INVESTIGATOR_610131] -like homolog y domains 2 (VEGF -R/TIE -2) inhibitor 11 -(2-methylpropyl) -
12,13 -dihydro -2-methyl -8-(pyrimidin -2-ylamino) -4H-indazolo[5, 4 -a]pyrrolo[3,4 -
c]carbazol -4-one (CEP -[ZIP_CODE]): a novel oncology therapeutic agent. J Med Chem  2012; 55(2): 
[ADDRESS_1137415] New Drugs  2014; 32(6): [ADDRESS_1137416]  2003; 112 (12): 1809 -20. 
15. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid 
tumours: revised RECIST guideline (versi on 1.1). Eur J Cancer  2009; 45(2): 228 -47. 
16. Cheng HH, Gulati R, Azad A, et al. Activity of enzalutamide in men with metastatic castration -
resistant prostate cancer is affected by [CONTACT_119492]/or docetaxel. 
Prostate Cancer Prostat ic Dis  2015; 18(2): 122 -7. 
17.    PASS 15:  Power and Analysis Sample Size Software ( 2017 ).   NCSS, LLC.   Kaysville, Utah, 
[LOCATION_003].  ncss.com/software/pass.  
18. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ 
DrugInteractionsLabeling/ucm093664.htm#inVitro  
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 60 of 67                                            Version date: 7/2/201 9   
 APPENDIX A: PERFORMA NCE STATUS CRITERIA  
ECOG Performance Status Scale  Karnofsky Performance Scale  
Grade  Description  % Description  
0 Normal activity. Fully active, able to 
continue all predisease performance 
without restriction . 100 Normal, no complaints, no evidence of 
disease  
90 Able to carry on normal activity, minor 
signs or symptoms of disease  
1 Symptoms, but ambulatory.  Restricted in 
physically strenuous activity but 
ambulatory and able to carry out work of a 
light or sedentary nature (eg, light 
housework, office work) . 80 Normal activity with effort, some signs or 
symptoms of disease  
70 Cares for self, unable to carry on normal 
activity or to do active work  
2 In bed < 50% of the time. Ambulatory and 
capable of all self -care but unable to carry 
out any work activities. Up and about more 
than 50% of waking hours . [ADDRESS_1137417] needs  
50 Requires considerable assistance and 
frequent medical care  
3 In bed > 50% of the time. Capable of only 
limited self -care, confined to bed or chair  
> 50% of waking hours . 40 Disabled, requires special care and 
assistance  
30 Severely disabled, hospi[INVESTIGATOR_374]. 
Death not imminent . 
4 100% bedridden. Completely di sabled, 
cannot carry on any self -care, totally 
confined to bed or chair . 20 Very sick, hospi[INVESTIGATOR_374]. Death 
not imminent . 
10 Moribund, fatal processes progressing 
rapi[INVESTIGATOR_375]  
5 Dead  0 Dead  
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 61 of 67                                                Version date: 7/2/201 9   
   APPENDIX B: MEDICATI ONS WITH THE POTENTI AL FOR DRUG -DRUG INTERACTIONS  
Please refer to Tables 3 -2 and 3 -3 of the FDA drug interactions labeling website for examples of 
clinical inhibitors and clinical inducers of P450, respectively.18 
Potent Inhibitors of CYP1A2, CYP2C8, or CYP3A4  
Potent inhibitors of the CYP1A2, 2C8, or 3A4 include, but are not limited to, the  following:  
CYP1A2  
Fluvoxamine  
Ciprofloxacin  
Mexiletine  
Propafenone  
Zileuton  
CYP2C8  
Gemfibrozil  
CYP3A4  
Ketoconazole  
Indinavir  
Ritonavir  
Itraconazole  
Clarithromycin  
Telithromycin  
Aprepi[INVESTIGATOR_820654].  
 
Potent Inducers of CYP1A2, CYP2C8, or CYP3A4  
Potent inducers of the CYP1A2, 2C8, or 3A4 include, but are not limited to, the  
following:  
CYP1A2  
Smoking  
CYP2C8  
Rifampi[INVESTIGATOR_820655]3A4  
Rifampi[INVESTIGATOR_820656].  
  
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 62 of 67                                                Version date: 7/2/201 9   
   Substrates of CYP3A4/5 With a Narrow Therapeutic Range  
Substrates of CYP3A4/5 with a narrow therapeutic range include, but are not limited to:  
Alfentanil  
Astemizole  
Cisapr ide 
Cyclosporine  
Diergotamine  
Ergotamine  
Fentanyl  
Pi[INVESTIGATOR_820657].   
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 63 of 67                                                Version date: 7/2/201 9   
   APPENDIX C: STUDY CA LENDAR   
 Screening  Treatment/Intervention Period  
End of Tx ([ADDRESS_1137418] dose)   
Cycle 1  Cycle 2 + beyond  Follow -up 
Q 3 mos  
 Day -28 to 
Day -1 Day  1  
(±3 d)  Day  8  
(±3 d)  Day  15 (±3 
d) Day 22 (±3 
d) Day 1  
 (±3 d)  (±3 d)   
Informed consent and research 
authorization/  HIPAA form  Xa        
Demographics, medical history, 
histologic and radiologic confirmation  
of disease  X        
Physical examination, vitals, weight, 
blood pressure  X X X X X X X  
EKG  X        
Height  X        
Performance status  X X X X X X X  
Concomitant meds  X X X X X X X  
Toxicity assessment  X X X X X X X  
Tumor measurementsb X Tumor measurements will be repeated every 8 weeks  (+/- 10 d)    
Laboratory testsc X  X X X X X  
Correlative samples  X     Xd X  
Tumor Biopsies  X     Xe   
Follow -up        Xf 
a. May be obtained up to [ADDRESS_1137419] or MRI abd/pel and a bone scan  or PET . Chest x -ray should be done if necessary for tumor assessment.  Radiologic documentation will 
be provided for patients removed from study for progressive disease.  
c. Complete blood count, comprehensive chemistry panel including renal function (BUN, creatinine) and liver function tests (AST,  ALT, total bilirubin), PSA, testosterone  (at baseline) . 
d. Whole blood samples will be collected every 4 weeks from screening to end of treatment (see lab manual).  
e. Tumor biopsies performed at the Cycle 3 visit ( week 8 , +/- 10 d)  (see lab manual).  
f. Patients will be followed  every three months for 5 years from end of treatment  for survival and subsequent treatment .  
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 64 of 67                                                Version date: 7/2/201 9   
   APPENDIX D: GLOSSARY OF ABBREV IATIONS AND ACRONYMS  
AE adverse event  
ALT  alanine aminotransferase  
AR androgen receptor  
AST  aspartate aminotransferase  
CFR  Code of Federal Regulations  
CRF  case report form  
CRPC  castration resistant prostate cancer  
CT computerized tomography  
CTC  circulating tumor cell  
CTCAE  Common Terminology Criteria for Adverse Events  
DLT  dose -limiting toxicity  
ECOG  Eastern Cooperative Oncology Group  
FDA  Food and Drug Administration  
FGFR1  fibroblast growth factor receptor [ADDRESS_1137420]  
IC50  50% inhibition of activity  
ICH International Conference on Harmonisation  
IEC Independent Ethics Committee  
IRB Institutional Review Board  
ITT intent -to-treat population  
LD longest diameter  
mCRPC  metastatic castration -resistant prostate cancer  
MTD  maximum tolerated dose  
MTKI  multi -tyrosine kinase inhibitor  
NCI National Cancer Institute  
NLCB  no longer clinically benefitting  
NOD  non-obese diabetic  
PCCTC  Prostate Cancer Clinical Trials Consortium  
PCWG3  Prostate Cancer Working Group 3  
PD progressive disease  
PFS progression -free survival  
PI [INVESTIGATOR_820658] -specific antigen  
PSA50  PSA ≥ 50% response rate  
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 65 of 67                                                Version date: 7/2/[ADDRESS_1137421]  Response Evaluation Criteria in Solid Tumors  
SAE  serious adverse event  
SCID  severe combined immunodeficiency  
SD stable disease  
TIE1, TIE2  tyrosine kinase with immuno globulin -like and EGF -like domains (1, 2)  
TMZ  temozolomide  
ULN  upper limit of normal  
VEGF  vascular endothelial growth factor  
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 66 of 67                                                Version date: 7/2/201 9   
   
APPENDIX  E.  
 
  
ESK981   
Karmanos Cancer Institute  2017 -065   
Esanik  Therapeutics Inc.                                                   Page 67 of 67                                                Version date: 7/2/201 9   
   APPENDIX F. DSM REPORT FORM  
 
1. Grade: 1 -Mild, 2 -Moderate, 3 - Severe, 4 -Life-threatening, or 5 - Death.  
2. Attribution: 1 -unrelated, 2 - unlikely, 3 - possibly, 4 - probably, or 5 - definitely   
OFF TREATMENT 
  Provide reason [progression, death, toxicity, completed therapy, etc].  
 
 
  
 
 
OTHER COMMENTS  
 
 
Investigator Signature:   [CONTACT_820694]:   
 PROTOCOL#:    REPORT DATE:       
                                                                                      
PROTOCOL TITLE  
 
PROTOCOL ACTIVITY SI NCE LAST REPORT  
Accrual Goal:  Eligible:   Total number of AE’s to date:  
 
Accrual to Date:   Ineligible:  
(provide reason):  
Accrual Since  
Last Monthly Report:     
SPECIFICALLY FOR PHA SE I TRIAL &/OR DOSE  ESCALATING TRIALS:  
DOSE LEVEL  ACCRUAL   
  
  
RECORD ALL GRADE 3, 4, AND 5 ADVERSE EVE NTS (AE).  GROUP BY [CONTACT_820685].   RECORD THE DATE OF T HE OCCURRENCE, 
ATTRIBUTION AND IF R EPORTABLE TO THE IRB .    SHADE THE ROWS OF THE AE’S THAT HAV E OCCURRED FOR THIS REPORT.  
ATTACH THE HIC UP RE PORT FORM FOR THESE REPORTABLE EVENTS TH AT OCCURRED ON THIS REPORT.  
Pt. ID#  Category and type of adverse reaction  
 Date of 
Occurrence  Grade1 Attribution2 Reportable to IRB (Y/N)  
Yes with date  
      
      